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was included. We developed an evidence map, undertook a narrative synthesis and identified research
gaps. A consultation exercise with stakeholders in India helped contextualise the review and identify ad-
ditional research priorities.ResultsTitles/Abstracts of 9699 articles were screened, full text of 282 obtained
and 80 were included. Research on the ethics of clinical trials/research covered a wide range of topics,
often conducted with little to no funding. Studies predominantly examined what lay (patients/public)
and professional participants (eg, healthcare staff/students/faculty) know about topics such as research
ethics or understand from the information given to obtain their consent for research participation. Easily
accessible groups, namely ethics committee members and healthcare students were frequently researched.
Research gaps included developing a better understanding of the recruitment-informed consent process,
including the doctor-patient interaction, in multiple contexts and exploring issues of equity and justice in
clinical trials/research.ConclusionThe review demonstrates that while a wide range of topics have been
studied in India, the focus is largely on assessing knowledge levels across different population groups.
This is a useful starting point, but fundamental questions remain unanswered about informed consent
processes and broader issues of inequity that pervade the clinical trials/research landscape. A priority-
setting exercise and appropriate funding mechanisms to support researchers in India would help improve
the clinical trials/research ecosystem.
DOI: https://doi.org/10.1136/bmjgh-2020-004729






The following work is licensed under a Creative Commons: Attribution 4.0 International (CC BY 4.0)
License.
Originally published at:
Paramasivan, Sangeetha; Davies, Philippa; Richards, Alison; Wade, Julia; Rooshenas, Leila; Mills, Nicola;
Realpe, Alba; Raj, Jeffrey Pradeep; Subramani, Supriya; Ives, Jonathan; Huxtable, Richard; Blazeby,
Jane M; Donovan, Jenny L (2021). What empirical research has been undertaken on the ethics of




 1Paramasivan S, et al. BMJ Global Health 2021;6:e004729. doi:10.1136/bmjgh-2020-004729
What empirical research has been 
undertaken on the ethics of clinical 
research in India? A systematic scoping 
review and narrative synthesis
Sangeetha Paramasivan   ,1,2 Philippa Davies,1,3 Alison Richards,1,3 Julia Wade,1 
Leila Rooshenas,1,2 Nicola Mills,1,2 Alba Realpe,1,2 Jeffrey Pradeep Raj,4 
Supriya Subramani,5 Jonathan Ives,6 Richard Huxtable,6 Jane M Blazeby,2,7 
Jenny L Donovan1,2
Original research
To cite: Paramasivan S, 
Davies P, Richards A, et al. 
What empirical research 
has been undertaken on the 
ethics of clinical research 
in India? A systematic 
scoping review and narrative 
synthesis. BMJ Global Health 
2021;6:e004729. doi:10.1136/
bmjgh-2020-004729
Handling editor Seye Abimbola
 ► Additional supplemental 
material is published online only. 
To view, please visit the journal 
online (http:// dx. doi. org/ 10. 
1136/ bmjgh- 2020- 004729).
Received 12 December 2020
Revised 13 February 2021
Accepted 24 February 2021
For numbered affiliations see 
end of article.
Correspondence to
Dr Sangeetha Paramasivan;  
 sangeetha. paramasivan@ 
bristol. ac. uk
© Author(s) (or their 
employer(s)) 2021. Re- use 
permitted under CC BY. 
Published by BMJ.
AbsTrACT
Introduction The post-2005 rise in clinical trials and 
clinical research conducted in India was accompanied 
by frequent reports of unethical practices, leading to a 
series of regulatory changes. We conducted a systematic 
scoping review to obtain an overview of empirical research 
pertaining to the ethics of clinical trials/research in India.
Methods Our search strategy combined terms related to 
ethics/bioethics, informed consent, clinical trials/research 
and India, across nine databases, up to November 2019. 
Peer- reviewed research exploring ethical aspects of clinical 
trials/research in India with any stakeholder groups was 
included. We developed an evidence map, undertook 
a narrative synthesis and identified research gaps. A 
consultation exercise with stakeholders in India helped 
contextualise the review and identify additional research 
priorities.
results Titles/Abstracts of 9699 articles were screened, 
full text of 282 obtained and 80 were included. Research 
on the ethics of clinical trials/research covered a wide 
range of topics, often conducted with little to no funding. 
Studies predominantly examined what lay (patients/
public) and professional participants (eg, healthcare staff/
students/faculty) know about topics such as research 
ethics or understand from the information given to 
obtain their consent for research participation. Easily 
accessible groups, namely ethics committee members 
and healthcare students were frequently researched. 
Research gaps included developing a better understanding 
of the recruitment- informed consent process, including 
the doctor- patient interaction, in multiple contexts and 
exploring issues of equity and justice in clinical trials/
research.
Conclusion The review demonstrates that while a wide 
range of topics have been studied in India, the focus is 
largely on assessing knowledge levels across different 
population groups. This is a useful starting point, but 
fundamental questions remain unanswered about informed 
consent processes and broader issues of inequity that 
pervade the clinical trials/research landscape. A priority- 
setting exercise and appropriate funding mechanisms 
to support researchers in India would help improve the 
clinical trials/research ecosystem.
InTroduCTIon
International clinical trials recruit partici-
pants from low- income and middle- income 
countries (LMICs) for economic, pragmatic 
and scientific reasons.1 Post-2005, when the 
World Trade Organisation- Trade Related 
Intellectual Property Rights agreement 
Key questions
What is already known?
 ► The increase in the number of clinical trials and clin-
ical research conducted in India after 2005 was ac-
companied by many reports of ethical misconduct, 
with bioethics reports and health activism prompting 
a series of regulatory changes by the government.
 ► While there was a corresponding increase in empir-
ical research on various ethical aspects of clinical 
trials/research in India, little was known about the 
scope of this research or what areas of research re-
quired further attention to improve the clinical trials/
research ecosystem.
What are the new findings?
 ► Research on ethical aspects of clinical trials/re-
search in India was often carried out with limited 
to no funding, covered a wide range of topics but 
with a focus on knowledge assessments of lay and 
professional groups on topics such as research eth-
ics, and leaned on easily accessible groups such as 
ethics committee members and healthcare students 
for study populations.
 ► A range of research gaps were identified, facilitat-
ed by a consultation exercise with key stakehold-
ers from India, and included developing a better 
understanding of the different components of the 
recruitment and informed consent process, such as 
the doctor- patient interaction, developing models of 
informed consent specific to the Indian context and 
exploring issues such as equity and justice within 
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What do the new findings imply?
 ► There is a need to move from knowledge assessments towards ad-
dressing other fundamental questions about recruitment, informed 
consent, equity and justice.
 ► The large number of research gaps identified warrants a locally 
led priority- setting exercise as well as appropriate funding mech-
anisms to support researchers in India to undertake clinical trials/
research methodology and ethics- related research.
became fully binding for India, the number of clinical 
trials approved by the Indian government’s regulatory 
authority, Central Drugs Standard Control Organisation, 
began to increase,2 peaking in 2010 followed by a sharp 
decline to 20133 (online supplemental file 1). An iden-
tical pattern of growth and contraction was observed in 
India’s clinical trial sector’s growth rate, in research using 
clinicaltrials. gov data.4
The downward trend is attributed to the chain of 
events that began with unacceptable ethical practices, 
such as failure to obtain participants’ informed consent 
for trial participation,5 being reported nationally and 
internationally.6–11 In 2013, the Supreme Court of India 
intervened and briefly halted approvals for new clinical 
trials12 in response to concerns for participant autonomy 
and safety, and public interest litigations from non- 
governmental organisations.13 14 New regulations were 
introduced in 2013 as amendments to Schedule Y of the 
Drugs and Cosmetics Rules 1945,15 mandating measures 
such as registration of ethics committees16 and audio- 
visual (AV) recordings of the informed consent discus-
sion,17 18 the latter being a requirement that is unique 
to India (see Gogtay et al18 for an overview of regulatory 
changes/requirements in India from 2005 to 2016). Also 
specific to India is that the term ‘clinical trial’ is limited to 
the study of ‘new drugs’ only, with Biomedical and Health 
Research (BMHR) referring to all other basic, applied, 
operational and clinical research19 (in contrast to broader 
definitions of ‘clinical trial’, which include medical, 
surgical and behavioural interventional research).20 21 
The most recent regulatory changes outlined in the New 
Drugs and Clinical Trial (NDCT) Rules of 201919 22 bring 
non- drug- related research (ie, BMHR) within the regu-
latory ambit for the first time19 23 (previously, regulatory 
mechanisms in India were principally focused on ‘new 
drug’ research). The NDCT Rules19 also separate the 
ethics and governance processes for clinical trials and 
bioavailability/bioequivalence studies from those for 
BMHR studies. For instance, two different types of ethics 
committees, each with separate authorities responsible 
for their registration and monitoring, will approve the 
two groups of studies. It is also now mandatory for BMHR 
ethics committees and academic clinical trials to adhere 
to the Indian Council for Medical Research’s National 
Ethical Guidelines for Biomedical and Health Research 
Involving Human Participants.24 25
Given this backdrop, there is a large body of theoret-
ical bioethics literature and commentary by researchers, 
advocacy groups and bioethicists, covering topics such as 
lessons learnt from conducting clinical trials,26–28 ‘stan-
dard care’ in clinical trials,29 30 structure of the clinical 
trial industry,31 informed consent placed within the wider 
socioeconomic context,32 role of ethics committees33 
and ensuring appropriate compensation mechanisms.34 
There has also been a corresponding increase in empir-
ical research on the ethics of clinical trials specifically and 
clinical research more broadly (henceforth clinical trials/
research) in India, which has not been comprehensively 
reviewed. We therefore sought to summarise this body of 
research evidence through a systematic scoping review 
and narrative synthesis to help identify research gaps.
MeTHods
We undertook a systematic scoping review following the 
established six- step framework by Arksey and O’Malley,35 
drawing from recommendations to enhance the method-
ology36–38 and adhering to the Preferred Reporting Items 
for Systematic Reviews and Meta- analysis extension for 
scoping reviews39 (online supplemental file 2).
An initial systematic review of clinical trial informed 
consent interventions in India (PROSPERO registra-
tion: CRD42017068966) was amended to a systematic 
‘scoping’ review (not within PROSPERO’s remit, hence 
withdrawn) of research on the ethics of clinical trials/
research in India, as the latter method is particularly 
useful when the aim is to map the evidence base in a 
broad but complex unreviewed area.35 37 38
Identifying the research question
We sought to obtain an overview of the empirical 
evidence in relation to the ethics of conducting clinical 
trials/research in India. More specifically, we aimed:
a. to map the empirical research undertaken on any eth-
ical aspect of conducting clinical trials/research in 
India;
b. to synthesise the key themes from this evidence base, 
with a focus on informed consent;
c. to identify gaps to inform future research priorities.
Identifying relevant studies
Inclusion criteria
The research questions were assessed in relation to the 
setting, population, phenomenon of interest and the 
study design of articles (online supplemental file 3). We 
included articles that reported (a) on original research 
in a peer- reviewed journal, (b) on India as a country 
for data collection (if study involved many countries, 
included if India- specific findings could be differenti-
ated), (c) on ethical issues in relation to clinical trials/
research and (d) with any key stakeholder groups—lay 
(public; clinical trials/research participants; patients/
guardians), professional (healthcare/research faculty, 
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regulatory/governmental agencies) or documents 
(informed consent forms; ethics applications).
Exclusion criteria
We excluded commentaries, ‘lessons learnt’ articles, 
abstracts, letters, audits (eg, Clinical Trials Registry- India 
audits,40 41 except when linked to an ethical issue), and 
studies from countries other than India (eg, studies 
exploring views of researchers from high- income coun-
tries undertaking research in LMICs).42 43 We excluded 
studies on the following topics:
a. Willingness to participate (WTP) in clinical trials/re-
search and recruitment- focussed studies, except when 
they considered ethical issues (there are other system-
atic reviews on WTP44–46; WTP components of includ-
ed studies were not considered in this review).
b. Informed consent/ethical issues in relation to pro-
cedures/treatment outside of clinical trials/research 
(eg, in routine surgery).47 48
c. Pharmacovigilance (PV) studies (there are systematic 
reviews on PV49; PV components of included studies 
were not considered in this review).
d. Other: studies on medical/healthcare/clinical ethics 
(ie, not in relation to clinical trials/research or re-
search ethics) and research skills/capacity with profes-
sional groups (eg, healthcare students).50 51
No restrictions were applied based on language, age 
(children/adult), study design or quality of research.
Search strategy
We searched the following nine electronic bibliographic 
databases with no start date and up to 5 September 2017 
and this was updated using the technique by Bramer 
and Bain52 to 12 November 2019: MEDLINE, Cochrane 
Library, Web of Science, Scopus, Embase, PsycINFO, 
Cumulative Index of Nursing and Allied Health Litera-
ture, International Bibliography of Social Sciences and 
Online Resource for Recruitment research in Clinical 
TriAls.53 Search terms relating to three domains were 
combined: (a) ethics, bioethics, informed consent; (b) 
clinical trials/research and (c) India. A comprehensive 
search strategy first developed on MEDLINE (SP) drew 
from systematic reviews on related topics,54 55 was refined 
by an information specialist (ARi) and adapted to the 
other databases (online supplemental file 4—MEDLINE 
search strategy). Searches included other South Asian 
countries to gather contextual information, but the 
review focused on India. We used a combination of 
Medical Subject Headings, text word searches and search 
strings using proximity indicators. We searched the refer-
ence lists of eligible research articles and ineligible key 
opinion/commentary pieces, and contacted authors of 
published conference abstracts to trace studies.
study selection
All articles identified from the databases and other 
sources were downloaded to EndNote- X956 and 
duplicates removed. Following the original search 
in September 2017, one reviewer (SP) screened the 
titles and abstracts of all articles with a 20% random 
sample screened independently by a second reviewer 
(PD). There was a high level of agreement across the 
two reviewers (disagreement in 3 of 1292 articles), 
with discrepancies discussed and resolved. Full text of 
all relevant articles were obtained and screened inde-
pendently by at least two authors (SP with NM, JW, LR). 
Discordance was again resolved through group discus-
sion among all four reviewers. Where it was unclear 
if an article or a particular topic should be included 
(eg, biobanking, data sharing), a decision was made by 
meeting with two content experts (ethicists JI and RH) 
and reviewing the articles together. For the search and 
screening update in November 2019, SP carried out all 
steps.
Charting the data: data extraction and quality assessment
A data extraction form was developed (SP) and inde-
pendently applied by two reviewers (SP and ARe) on a 
sample of articles (n=10). The form was refined after 
discussion and captured the following information (SP, 
ARe, JPR, SS): authors, year of publication and data 
collection, location, study aim, topic area, population, 
study design/methods, participants and findings. Subse-
quently, further information was captured on (SP): (a) 
whether studies were conducted within the context of a 
real or hypothetical study/scenario and (b) whether they 
explored broad (eg, clinical trials/research, research 
ethics) or specific topics (eg, data sharing, compensa-
tion).
Two review authors (SP with LR, JW, PD, JPR, SS) 
independently assessed the quality57 of the majority of 
studies using the following tools: Critical Appraisal Skills 
Programme (CASP) checklist58 for qualitative studies; 
Appraisal tool for Cross- Sectional Studies (AXIS; adapted 
to have 14 items instead of 20)59 for quantitative studies 
and AXIS, CASP and a section of the Mixed Methods 
Appraisal Tool60 for mixed methods studies. Quality 
assessments were discussed to resolve discrepancies and 
used to summarise relevant methodological issues in the 
narrative synthesis.
Collating, synthesising and reporting the results
We first quantified the data in relation to the study char-
acteristics. Next, we created an evidence map to visualise 
the volume of studies by topic, population group and 
methods. Finally, we synthesised the quantitative and 
qualitative findings reported in included studies, using 
EndNote- X956 for data management and MaxQDA-1261 
for coding articles, and used narrative and thematic 
description to write detailed descriptive accounts. The 
synthesis broadly followed the categorisations in the 
evidence map, but looked across all included articles to 
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Consultation
The consultation phase, considered optional in scoping 
reviews,35 took place after the synthesis, with the aim of 
informing the review and ensuring local priorities and 
context were accounted for. We approached colleagues 
in India who were researchers, ethicists and represent-
atives from advocacy groups, through prior networks 
or because they had authored seminal empirical and/
or conceptual papers (online supplemental file 5—
consultation members). Consultation was carried out 
via virtual conferencing, email and telephone. Findings 
and research gaps identified through the review were 
discussed. Key recommendations made by stakeholders 
were grouped by topic and incorporated in the manu-
script, tables or supplements.
Patient and public involvement
No patients or members of the public were involved in 
this review.
resulTs
description of included studies
A total of 9699 unique records were identified (original, 
updated and manual searches), of which 282 full- text 
articles were assessed against the inclusion/exclusion 
criteria and 80 included62–141 (figure 1). Key study char-
acteristics are summarised in table 1 (individual study 
details are in online supplemental file 6).
Most studies were conducted in urban settings (47/80), 
in the western (24/80) and southern (21/80) parts of 
India. Studies were mainly quantitative (60/80), ques-
tionnaire surveys (36/60), conducted with professional 
groups (34/80) and appeared in journals published in 
India (49/80), primarily the Indian Journal of Medical 
Ethics142 and Perspectives in Clinical Research143 (n=15 and 
16, respectively).
There were no research studies published on the 
ethical issues around conducting clinical trials/research 
until 2008, with a large proportion published a few years 
before and after the landmark regulatory changes of 
2013 (53/80 were published 2011–2016; online supple-
mental file 1). Many studies did not mention the year of 
data collection (27/80) and of those that did, only a few 
were carried out in/after 2013 (17/53).
Corresponding authors of most studies were based 
within academic institutions (69/80; 15 outside India 
and 54 within India), primarily within Departments of 
Pharmacology of various Indian institutions (24/54). 
Seth Gordhandas Sunderdas Medical College and King 
Edward Memorial Hospital, Mumbai had the most 
number of corresponding authors (12/54), followed by 
Christian Medical College, Vellore (5/54). Two- thirds 
of studies (53/80) did not provide information on their 
funding source (26/53) or stated they did not receive 
any funding (27/53); of the remaining, 21 were funded/
supported by international grants, 4 by intramural grants 
and 2 by pharmaceutical companies. There was no state-
ment on conflicts of interest in 28 studies.
evidence map: research on ethical aspects of conducting 
clinical trials/research in India
We developed an evidence map that charts the total arti-
cles included (n=80) by the main focus of the topics and 
population covered in the studies, alongside the methods 
used (table 2).
Primary research (n=58): more than half (32/58) were 
studies exploring knowledge (with or without attitude 
and practice components) of participants on topics such 
as information provided to obtain informed consent 
(primarily with lay participants), clinical trials/research, 
research ethics and ethics committees (primarily with 
professional participants), and were mainly quantitative 
(27/32). Studies that assessed comprehension of the 
informed consent form or verbal information provision 
(n=10) were carried out in real (8/10) and hypothet-
ical (2/10) randomised controlled trials (RCTs), clinical 
trials and cohort studies.
Another large group of primary research studies 
(26/58) focused on perceptions, experiences and 
practices/processes on topics such as the extent of 
patient participation in informed consent discussions, 
AV recording of consent processes, ethics committees, 
research governance (eg, data sharing) and the larger 
clinical trials landscape in India (such as outsourcing, 
contract research organisations and civil society organi-
sations). Studies employed a wider range of methods (11 
quantitative, 13 qualitative studies, 2 mixed methods) 
and some (9/26) were conducted in the context of a real 
and/or hypothetical study.
Secondary research (n=22): these studies were all quan-
titative and were centred around documentary reviews 
of the quality of application forms submitted to ethics 
committees, compliance of informed consent documents 
to guidelines/regulations, and Indian journal articles’ 
reporting practices on informed consent and ethical 
approval.
narrative synthesis: key findings and research gaps
The findings from included studies were synthesised 
based on population groups (lay/professional) and key 
topic areas, with summaries of methodological issues 
where relevant. Sections A1–A6 and B1 indicated below 
correspond to those in table 3, which highlights the key 
findings from the synthesis alongside identified gaps (see 
online supplemental file 7 for full report of synthesis).
Primary research was synthesised in six key areas (A1–
A6). The first four (A1–A4) covered studies that involved 
comprehension of the informed consent form and 
knowledge of clinical trials/research, research ethics and 
ethics committees (where attitudes and/or practices were 
reported, these were synthesised). Research on informed 
consent processes (A5) and broader cross- cutting themes 
that provided a more holistic understanding of the clin-









































































































































September 2017 Records 
identified through 
database searching 

































Other searches: Records 
identified through other 
sources, including 
manual search 
(n = 17*) 
 
Records after duplicates 
removed 
(n = 6459) 
Total unique records screened (abstract/title) 
(n = 9699) 
Records excluded 
(n = 9417) 
Studies included in 
review 
(n = 80)† 
Full text articles 
assessed for eligibility 
(n = 282) 
Articles excluded n=202: 
• 80 commentaries, abstracts, letters, 
guideline reviews, lessons learnt 
• 27 studies outside India  
• 5 audits (without ethics angle) 
• 90 primary research studies with 
topics outside search remit 
o 31 Recruitment focus only 
o 21 Pharmacovigilance 
o 5 Informed consent/ethics in 
routine procedures 





(n = 9156) 
New search: November 
2019 Records identified 
through database 
searching 
(n = 14806) 
New records identified 
(n = 3223) 
Quantitative studies  
(n = 60) 
Qualitative studies   
(n = 16)
Mixed methods 
(n = 4) 
Figure 1 Preferred Reporting Items for Systematic Reviews and Meta- analysis flow diagram.160 *One study was identified 
through the consultation exercise. †This includes articles that reported on different aspects of the results derived from the 
same dataset73 92 93 107 108 or on different datasets obtained through the same grant.113 114 120 126 127 160
research (B1) was synthesised based on the type of docu-
ments scrutinised (eg, ethics application forms, informed 
consent documents, journal articles) and the area under 
investigation (eg, completeness, errors, quality; reporting 
practices). The number of articles tagged to a given topic 
includes studies where that topic was the main focus 
as well as those where the topic was briefly explored. 
Salient findings from the synthesis are presented below 
narratively.
Primary research
The synthesis (table 3) established that, despite the focus 
on knowledge- based studies evident in the evidence map 
(table 2), it was difficult to build a coherent picture of 
lay and professional participants’ understanding of the 
topics explored (written/verbal information provision, 
clinical trials/research, research ethics, ethics commit-
tees), primarily due to the methodological (eg, validity of 
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Table 1 Key characteristics of included studies
Key characteristics (total n=80) N %
1. Location
a. Type
  Urban 47 58.8
  Rural 3 3.8
  Mixed 3 3.8
  Not available*/Not applicable† 27 33.8
b. Region
  West 24 30
  South 21 26.3
  North 10 12.5
  East 2 2.5
  Mixed (two studies in west and south; two 
in west, south and north)
4 5
  Pan India‡ 12 15
  Not available 7 8.8
2. Methods
a. Quantitative 60 75
  Surveys (inferential) 21
  Surveys (descriptive) 15
  Documents (descriptive) 13
  Documents (inferential) 4
  Other (documents, data, observation, RCT, 
websites)
7
b. Qualitative 16 20
  Interviews 10
  Interviews and focus groups 3
  Interviews and observations 2
  Interviews, observations, focus groups 1
c. Mixed methods 4 5
  Survey (descriptive) and interviews 2
  Survey (descriptive) and focus groups 1
  Survey (inferential) and focus groups 1
3. Population
a. Professional 34 42.5
  Ethics committee members 8
  Researchers (two with CT investigators; two 
with clinical research professionals; one 
with CRO staff)
5
  Healthcare students (five with medical 
students; one each with nursing and 
pharmacy students)
7
  Healthcare faculty (two with dental faculty; 
one with medical faculty)
3
  Healthcare students and faculty (two with 
dental students and faculty; one with 
medical students and faculty)
3
  Healthcare service providers (one with 
healthcare faculty)
3
  Mixed professional groups 5
Continued
Key characteristics (total n=80) N %
b. Lay 17 21.3
  RCT/CT participants (including parents/
guardians, healthy volunteers)
6
  Cohort study participants (including 
parents/guardians)
3
  General public (including those accessed 
from hospitals)
6
  Specific patient groups (HIV- positive 
patients; mental health service inpatients)
2
c. Documents 22 27.5




  a. Published in India 49 61.3
  b. Published in a high- income country 29 36.3
  c. Unknown/not clear 2 2.5
*When information is not reported.
†When data collected is documents.
‡Includes surveys, documents, journal articles, websites that were not 
specific to one region.
CRO, contract research organisation; CT, clinical trial; RCT, 
randomised controlled trial.
Table 1 Continued
(A1–A4). Methodological research aimed at developing 
locally validated tools to assess knowledge will help 
improve the quality of future studies and facilitate meta- 
analysis.
Ethics committees (A4) were among the most studied 
topics (18 studies) and also the source of data in a large 
volume of studies (16 studies, 8 each with committee 
members and documents submitted to/produced by 
committees). Studies highlighted a number of challenges 
faced by ethics committees73 92 101 102 108 121 130 (eg, conflicts 
of interest, onerous workload, impact of frequent regula-
tory changes without support for implementation), which 
would benefit from the development of interventions to 
support the optimal functioning of ethics committees. 
Healthcare students were the next most researched 
group (10 studies).
Research on interventions to optimise comprehension 
of written/verbal information provision for informed 
consent (A1) were particularly lacking (except one RCT 
that compared group and individual counselling and 
found no difference in comprehension).116 While there 
is some evidence of the difficulties of communicating 
research terminology (around terms such as research, trial, 
randomisation) particularly in local languages,70 112 127 
research is required on interventions to overcome these 
barriers (A2). There was overwhelming support for 
education and training on clinical trials/research and 
research ethics in the curriculum for key stakeholder 
groups, including healthcare students75 81 98 131 137 but 
we do not know what, if any, aspects of these topics are 
currently covered in healthcare students’ curriculums so 
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Table 3 Summary of synthesised findings and gaps
Topic Summary of synthesised findings Research gaps
A. Primary research: knowledge (or awareness/comprehension) research (with or without attitudes/perceptions and practice/behaviour (or process) components)
A1. 
Comprehension 









lay (and some 
professional) 
participants
Number of studies 
tagged to topic=10
 ► Studies were questionnaire surveys that varied in methodological quality, with most deficiencies being in 
relation to survey instruments and reporting practices.
 ► Comprehension regarding a large number of aspects were studied among lay participants and reported 
to be poor on simple (eg, condition under study)117 as well as advanced concepts (eg, randomisation 
and blinding).65 116 Findings were mixed in relation to comprehension of some key concepts such as 
participant rights—some studies reported participants appeared well aware of their rights,62 78 82 87 
while others noted superficial rather than detailed understanding (eg, being aware of the voluntary 
nature of participation but not of freedom to decline participation or withdraw without facing adverse 
consequences).116 117 Comprehension among professional participants (medical and nursing students) 
was reported as insufficient.91 104 Except for one RCT that compared different methods of counselling for 
informed consent (group and individual; no difference in comprehension found),116 there were no other 
interventional studies aimed at identifying strategies that may help improve informed consent. A critical 
examination of what may constitute optimal understanding or information provision was lacking. The 
rationale for assessing comprehension was not always clear—only a few mentioned using the outcome to 
provide further information to participants on topics in which they had a lower score.
 ► (for A1- A4)
 ► Despite a large proportion of studies focusing on 
knowledge (and attitudes and practices), primarily 
through questionnaire surveys, it is as yet unclear 
(a) what aspects of clinical trials/research were often 
better or poorly understood by lay participants from 
the informed consent form and verbal information 
provision, (b) what, if any, aspects of clinical trials/
research, research ethics and ethics committees 
participants (primarily professional) were familiar 
with.
 ► There is a need for cross- cultural adaptations of 
questionnaires used in other countries and/or the 
development of locally validated survey tools to 
assess knowledge and comprehension.
 ► Research focused on knowledge should also 
critically examine and report on (a) the purpose of 
doing this (eg, whether assessing comprehension of 
informed consent would change local practice) and 
(b) what constitutes optimal understanding (among 
research participants) and optimal information 
provision. Developing a core information set for 
minimum baseline information to be conveyed to 
patients is crucial.
 ► There is an immense gap in knowledge regarding 
interventions that can potentially improve 
comprehension of research participants in India.
 ► Research is also needed on interventions aimed at: 
improving communication of research terminology 
in local languages, evaluating current clinical trials/
research and research ethics coverage in healthcare 
students’ curriculum and ways to optimise it, 
improving knowledge of these topics among 
healthcare providers and faculty.
 ► Qualitative research studies that chart the actual 
practice of informed consent rather than the 
reported practice of it are needed.
 ► Given the existing large volume of studies on ethics 
committees, research is needed on interventions 
that support and optimise the functioning of 






generally (not in 
the context of 
specific studies):
i. Lay participants




Number of studies 
tagged to topic=5
 ► Similar to studies above, the methodological limitations of this group of primarily questionnaire surveys 
hamper a robust understanding of lay and professional participants’ knowledge and attitudes to clinical 
trials/research.
 ► Knowledge: the synthesis of findings suggests limited to poor awareness of clinical trials/research among 
lay88 113 134 140 and professional participants75 112 131 (healthcare professionals such as doctors, nurses, 
counsellors and healthcare faculty and/or students from medicine and pharmacology). There was wide 
variation in the proportion of lay participants (~25%–60%) who had heard of clinical trials/research69 113 134 
and lack of familiarity with the English term ‘clinical trial’ among professional participants112 and the word 
‘research’ or its local translations among lay participants.127 Lay and professional groups were unfamiliar 
with the regulations required for biomedical research and/or clinical trials in particular.75 100 127 129
 ► Attitudes: studies reported generally positive attitudes towards clinical research and its potential benefits 
across lay and professional groups.69 75 113 122 127 131 134 Lay participants’ concerns revolved around 
confidentiality, compensation for participation and adverse outcomes, unethical trial conduct and lack of trust 
in pharmaceutical research.69 122 127 134 Professional participants had negative attitudes towards pharma or 




and practices in 




(and some lay) 
participants
Number of studies 
tagged to topic=16
 ► As above, these were primarily questionnaire surveys with methodological limitations that limit the 
synthesis of participants’ (mostly professional and some lay) knowledge, attitudes and practices in 
relation to research ethics and informed consent (eg, many studies did not report if participants had 
prior clinical trials/research training/experience). Studies were primarily with dental and medical students 
and/or faculty and professionals from clinical research organisations, and some with ethics committee 
members, investigators and lay participants.
 ► Knowledge: some studies found poor or limited knowledge (self- reported or assessed) of research ethics 
and ethical guidelines among professional groups,77 81 137 while others reported good knowledge but poor 
attitudes and practices in relation to some aspects of informed consent and research ethics81 98 132 137 138 
(eg, some support for fabricating data to improve research outcomes if it did not harm patients and 
willingness to undertake research rejected by ethics committees).
 ► Attitudes: there were generally positive attitudes amongst professional participants towards procedural 
aspects ofinformed consent81 98 137 (such as informing patients of risks/benefits and obtaining signatures 
of participants), but concerns existed amongst lay and professional groups whether the informed consent 
process and documentation truly protect and inform patients.67 127 There was overwhelming support for 
research ethics education for keystakeholders (health students, researchers, ethics committee members),81 98 
137 but no research on what, if anything, was currently covered in the medical/dental curriculum.
 ► Practice: there was wide variation in the reported practice of informed consent and some indication of 
unsatisfactory practices in relation to research ethics and conduct77 135 138 (eg, in relation to carrying out 
informed consent in local languages, providing a copy of the consent documentation to patients and 
maintaining accurate patient records for research). There was indication of coercion among professional 
participants126 (medical students) and instances of inadequate informed consent and therapeutic 
misconception among lay participants.103 We do not know what information patients expect to be 




and practices in 
relation to ethics 
committees: 
Professional 
(and some lay) 
participants
Number of studies 
tagged to topic=18
 ► Ethics committees were among the most researched topics, primarily through questionnaire surveys, 
with similar methodological limitations as above (eg, missing information on participant demographics 
and prior training/experience on relevant topics). Studies were conducted with dental and medical 
professionals (students and/or faculty), ethics committee members, staff from clinical research 
organisations and lay participants.
 ► Knowledge: the synthesis suggests limited knowledge (self- reported and assessed) of ethics committee 
functioning and composition among medical and dental professionals81 97 102 135 137 (eg, on quorum requirements, 
lay representation and frequency of meetings). Lay participants were unaware of role of ethics committees in 
protecting patient rights.127
 ► Attitudes: there was widespread support for the existence and need for ethics committees and ethical review 
amongst dental professionals,81 98 137 but variation in satisfaction (high67 to limited108 135) regarding ethics 
committee functioning amongst professional groups (medical and contract research organisation staff). Reported 
challenges faced by ethics committees (as perceived by contract research organisation staff) included conflicts 
of interest that compromised their independence and pressures from senior management.133 The evolution 
of stricter regulations and guidelines was described favourably by ethics committee members, but they also 
felt they were too frequentand too many76 121 with numerous challenges in implementing some of the newer 
regulatory changes76 (such as renewal of committee registration). There was overwhelming support for a single 
national research ethics committee to consider multi- centric trials to prevent ‘ethics committee shopping’ (where 
investigators went to different committees until they obtained approval) amongst contract research organisation 
staff89 108 but lesser support amongst committee members.76 Views on how wide the remit of ethics committees 
should be varied across professional groups (from monitoring serious adverse events to imparting research ethics 
education to investigators and conducting ongoing monitoring of trials and on- site visits).68 101 102 108
 ► Practice: research on ‘practice’ related aspects of ethics committees suggests there were many areas of 
concern in relation to their functioning and composition92 (eg, arbitrariness in member selection and lack of 
choice in refusing membership amongst those affiliated to institutions), responsibilities92 101 102 (eg, some 
committees undertook monitoring of ongoing trials and on- site visits, while others did not), workload73 92 102 108 
130 (frequently described as onerous), the ethics review process73 101 102 (eg, lack of uniformity in documents 
and ethical aspects reviewed and guidelines followed) and the dilemmas faced in being expected to align with 
the international standards for ethical review and the increasing pharmaceuticalisation of society, while also 
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Topic Summary of synthesised findings Research gaps




lay (and some 
professional) 
participants
Number of studies 
tagged to topic=13 
(of which only 5 
were focused on 
topic)
 ► A small group of studies (n=5) explored the processes involved in informed consent, with a further 
few (n=8) briefly touching on the topic. Only one study70 detailed the process of customising the 
informed consent process to the study population (in an RCT with people with schizophrenia) 
through feedback from participants/caregivers and then evaluating the process from multiple 
perspectives. Use of a flip- chart during informed consent and training/ongoing support were 
found to be useful by participants/study personnel, while research terminology (trial/research, 
randomisation) was reported as difficult to convey.70
 ► Patient participation in informed consent discussions: questions asked by parents/guardians of potential 
child participants (infants) in informed consent discussions varied from 13% to 55% in two studies,83 111 
with education and higher socioeconomic status reported as associated with asking questions.83 111 127 
In healthy volunteer studies, concerns raised by participants revolved mainly around the payment than 
about their own health.
 ► Recruitment process/experience and informed consent process: one study reported on the involvement of 
paid middlemen to recruit healthy volunteers for bioavailability/bioequivalent studies, serial participation 
among volunteers and the informed consent process being a mere formality (as decision to participate 
was often made prior to that). Contrary to views of family involvement in informed consent, healthy 
volunteers were mostly unaccompanied and had not informed their families of participation due to 
concerns about being perceived as selling their bodies for money.140
 ► AV recording of informed consent discussions: acceptability of and support for AV recordings varied (a 
third of lay participants refused in a hypothetical study and nearly all agreed in a real vaccine trial72 83; 
a third to two- thirds of investigators were in support.79 89 133 Concerns included the increase in time/
resources required to carry out AV recordings and the lack of adequate guidance and support.79 83 89 
Some ethics committees reported reviewing the recordings if there was a need (ie, non- compliance/
protocol deviations in the informed consent process).76 Some investigators believed that the AV 
recording of the consent process would improve informed consent83 89 109 (eg, by increasing investigator 
responsibility), with one study reporting that study participants had better comprehension scores after 
mandatory AV recording of consent process than before.78
 ► (for A5)
 ► Gaps exist in our understanding of (a) models of 
informed consent that are tailored to the Indian 
context (ie, community- family based and/or 
Western- individual autonomy based; in the context 
of language diversity, illiteracy, health literacy), 
(b) informed consent/assent in children’s clinical 
research (c) informed consent processes across 
different contexts (industry or investigator led; 
student- led trials in medical institutions; healthy 
volunteer studies and vaccine trials), including 
recruitment interactions with potential participants 
and (d) The dual role played by many trial recruiters, 
where they are also the doctor/healthcare provider 
and the conflicts of interest and therapeutic 
misconception arising from same.
 ► Research examining the usefulness of mandatory AV 
recordings (eg, how often are they accessed for the 
purpose that they were made mandatory for) and 
ways in which existing AV recordings can be used to 
optimise informed consent are needed.
A6. Bigger picture: 
professional 
(and some lay) 
participants
Number of studies 
tagged to topic=20 
(of which only 7 
were focused on 
topic)
 ► There were a few (n=7), primarily qualitative, studies that explored the larger landscape within which  
clinical trials were conducted. Four cross- cutting themes were identified, drawing from other  
studies (n=13).
 ► Compensation (n=10): the synthesis revealed a nuanced discussion among professional and lay 
participants in relation to compensation for free medicines, for participation and for study- related 
injuries/serious adverse events. For instance, while lay participants from higher socioeconomic 
groups felt that the product (vaccine) should be free as it was still being researched, those 
from lower socioeconomic groups perceived free as inferior or dangerous.127 Knowledge of and 
compliance with national laws and guidelines regarding compensation for clinical trial- related 
injuries varied among investigators, ethics committee members and sponsors (reported as aware 
to lacking in clarity) and lay participants (reported as completely unaware).103 125 There was lack 
of uniformity in how and by whom compensation was determined (eg, by ethics committees, 
sponsor or investigators) and for what purposes (eg, lost wages, travel, participation, injuries or 
their management),76 103 125 with some evidence of healthy volunteers being able to bargain for 
incentives higher than what was approved by ethics committees.140
 ► Sharing of data, blood/tissue samples, results and benefits (n=3): the limited experience of 
participants (lay and professional) in relation to data sharing amplified their concerns about 
it.84 Despite the small number of studies on the topic, issues were well explored in relation to 
what is data,84 views on sharing of blood/tissue/medical records (lay participants often readily 
agreed at the start but were more discerning when given further information),127 different types of 
consent for data sharing84 127 (eg, blanket/broad, middle or explicit consent), disclosing individual 
findings following the use of biobanking research128 (eg, there was some support for disclosing 
actionable individual results, while recognising the challenges to the process and contrasts 
with high- income countries where individual results are usually not shared), sample ownership 
in biobanking research128 (eg, patients’, custodians’ or researchers’) and benefit sharing127 128 
(eg, giving back to the community, especially when outcomes of studies are commercialised for 
profits).
 ► Power imbalances (n=17): unequal power dynamics were explored across different groups and 
contexts. These ranged from local issues such as lay members of ethics committees feeling 
stifled by medics and scientists92 133 and paternalistic doctor- patient relationships contributing 
to therapeutic misconception about clinical trials,127 to larger issues such as the lack of 
correlation between India’s disease burden and its clinical trials,90 92 capacity building being 
more about implementation of agendas set by international pharma companies and procedural 
efficiency than the nurturing of local innovation and leadership,114 115 the exploitation of 
disadvantaged groups in clinical research103 105 114 140 (eg, targeting of recruitment within 
poor, rural, tribal and unemployed groups), paid healthy volunteers being exploited due to 
their lower socioeconomic status while also being able to bargain for higher incentives than 
approved by ethics committees (many viewed trial participation as an alternative career)140 
and ethical variability and the continuation of a neo- colonialist relationship between the 
West and India.109 112 113 121 The larger issues were highlighted by members of civil society 
organisations and ethics committee members, but less so by those from the private sector 
and contract research organisations, who argued against ethical variability across the West 
and India and felt that clinical trials were relevant to the needs of India.67 90 Patient and public 
involvement was under- researched, except for one study on community engagement.89
 ► CROs, CSOs and the clinical trial industry (n=7): some studies provided a detailed account of 
the growth of CROs in India (with ‘big- pharmaceuticalisation’ used to describe Indian pharma 
companies’ move from generic drug manufacturing to innovative research), CRO operations 
and processes employed for recruitment (in the context of healthy volunteers)140 and the vital 
role played by CSOs in changing the regulatory landscape in India114 115 (few other studies also 
explored related topics140). CRO staff were critical of reports of malpractice, but saw these as 
issues within other rather than their own CROs (although there was evidence to the contrary).115 140 
There was some distrust of pharma- sponsored trials among doctors, ethics committee members 
and CSO staff,75 92 114 while investigators from the private sector (in a study authored by 
researchers from a pharma company) expressed favourable views regarding pharma- sponsored 
trials.67 CSO members were supportive of RCTs, but lamented the lack of focus on wider ethical 
issues that went beyond procedural and informed consent focused agendas. Their accounts 
drew from interpretations of a social justice- based approach to health, while also highlighting 
an evolution of their views from the purely ideological to the more pragmatic (a move away from 
dichotomies such as Indian/public- good and foreign/private- bad).114
 ► (for A6)
 ► Although few in number, existing studies provide 
rich insights on the Indian clinical trials landscape.
 ► Research on real compensation awards, especially 
for study- related injuries, would help chart out 
current practice, so that recurrent areas of concern 
can be addressed. The challenges with the 
implementation of compensation rules could be 
explored in future studies, especially in light of the 
recent NDCT Rules, 2019.
 ► Empirical information on participant profiles across 
a range of clinical trials will help inform debates 
around the recruitment of vulnerable groups.
 ► Similarly, qualitative research on doctor (or 
recruiter)- patient interactions would provide 
empirical evidence on aspects of communication 
that contribute to or strengthen therapeutic 
misconception in trial recruitment (so that 
interventions can be developed to optimise 
communication).
 ► The impact of the NDCT 2019 Rules in redressing 
concerns such as conflicts of interest and power 
imbalances within ethics committees would need to 
be examined.
 ► Further research, especially qualitative, to expand 
the scope of discussion on issues of equity and 
justice in clinical trials in India and the role of social 
determinants such as gender, poverty, caste and 
their intersectionality would add to the existing rich 
but small number of studies on the topic.
 ► There is an immense gap in relation to research on 
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Number of studies 
tagged to topic=23
 ► Documents, primarily sourced from ethics committees (such as informed consent documentation, 
application forms, meeting minutes, site visits, approval letters) were examined for quality, coverage 
of issues such as compensation and compliance with legal frameworks and good clinical practice 
guidelines. Documentary research highlighted inadequate informed consent documentation,119 increased 
workload for ethics committees after the regulatory changes of 2013,66 inequities in the distribution of 
clinical trials, medical colleges and ethics committees across different states in India (reflecting existing 
health inequalities),106 mismatch between India’s disease burden and areas researched in clinical 
trials,139 141 evidence of ‘ethics shopping’ (multicentric studies that had not resolved queries raised 
by one ethics committee were found to have gained approval at another committee),96 inadequate 
mention of compensation arrangements in ethics committee application forms and informed consent 
documents64 99 107 120 125 (with some indication of improvements over time). Where readability of informed 
consent forms was examined, it was through Western readability tests.86 107
 ► A small group of studies also looked at reporting practices in journals from India, mostly in relation 
to ethical approval and informed consent, and found that this information was often missing or 
suboptimal.63 71 74 94 Methodological and ethical issues were found to be better reported in the clinical 
trials registry in India than in journals.124
 ► (for B1)
 ► Empirical evaluations of the regulatory processes, 
including number of trial applications submitted 
for approval per year, numbers approved and 
disapproved and reasons for the same, will help 
researchers better understand how regulations are 
applied to trial applications.
 ► Research to develop readability tests in Indian 
languages may help in improving informed consent 
forms, which could also be examined for issues 
beyond compliance with legal frameworks/
guidelines (such as whether trial treatments are 
presented in a balanced manner).
 ► Studies on reporting practices of surveys published 
in Indian journals would help highlight the key 
methodological issues that can be improved.
AV, audio- visual; CRO, contract research organisations; CSO, civil society organisations; RCT, randomised conrolled trial.
Table 3 Continued
There is some evidence in relation to the ‘reported’ 
practice of informed consent77 126 135 138 (eg, not 
conducting informed consent in local languages or 
indication of coercion among student research partici-
pants), but limited70 83 111 140 information on the ‘actual’ 
practice of gaining informed consent, what research 
participants consider important to know or models of 
informed consent that are tailored to the local context 
(A3, A5). Where ‘actual’ practice was examined, it was 
illuminating—for instance, in healthy volunteer studies, 
informed consent appeared to be a formality and discus-
sions were centred around payment for participation 
than risks to volunteers’ health.140 Future research on 
informed consent processes should include an in- depth 
exploration of the recruitment interaction with potential 
research participants that delves beyond the questions 
participants ask, towards the identification and dissem-
ination of good practice, across multiple contexts (eg, 
consent/assent in trials with children; student- led trials 
in academic institutions). A good starting point would be 
to explore if it is feasible, within the current regulatory 
framework and following strict confidentiality require-
ments, to use the AV recordings of the consent process 
more proactively for these purposes, rather than be 
reviewed only when there are reports of ethical miscon-
duct.76 Similarly, the development of core information 
sets that help define the essential information that partic-
ipants would like to receive is warranted (A3, A5).
The small group of studies (A6; seven studies) that 
focused beyond the surface issues around clinical trials 
provided rich insights into the origins, growth and 
workings of the clinical trials industry, while placing the 
industry within the wider regulatory environment and 
existing health inequities. Four key cross- cutting themes 
were examined among these primarily qualitative studies 
(informed by other qualitative/quantitative studies that 
touched on similar areas):
i. Compensation (for study participation, treatment or 
study- related injuries) was well researched and stud-
ies highlighted the need for a nuanced consideration 
of compensation arrangements127 (to account for 
views such as free treatment being perceived as infe-
rior/dangerous by those from lower socioeconomic 
groups). It also appeared that compensation deter-
mination is fraught with challenges76 103 125 140 (such 
as lack of uniformity in the process and incentives 
approved by ethics committees being overridden). 
Studying current practice in relation to actual com-
pensations that have been awarded may help chart 
out areas of inconsistencies that can be addressed. 
Also, there appear to be challenges with implement-
ing and complying with the compensation rules, 
which could be investigated in future studies (no 
studies were conducted after NDCT Rules 2019).
ii. Data sharing was explored in a small volume of stud-
ies84 127 128 that nonetheless provide valuable insights. 
For instance, lay participants appeared cautious 
about consent for data sharing after receiving de-
tailed information (despite readily agreeing initial-
ly)127 and some professional participants supported 
sharing clinically relevant and actionable results with 
individuals who contributed to biobanking research, 
but acknowledged the challenges to this process.128
iii. Power imbalances within the clinical trials/research 
environment were frequently discussed by profes-
sional participants, especially members of ethics com-
mittees and civil society organisations. Imbalances of 
concern included the paternalistic doctor- patient 
relationship contributing to therapeutic misconcep-
tion127 (where participants perceive unproven trial 
treatments to be beneficial), the lack of correlation 
between India’s disease burden and diseases stud-
ied,90 92 the equation between paid healthy volunteers 
(exploited due to their lower socioeconomic status) 
and contract research organisations (with whom the 
volunteers have bargaining power),140 capacity build-
ing that does not foster local innovation114 115 and the 
hierarchy between medical and non- medical experts 
in ethics committees.92 108 133 Some of these concerns 
would benefit from empirical investigation—for in-
stance, studying the doctor- patient interaction in tri-
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communication that contribute to therapeutic mis-
conception. Similarly, research, particularly qualita-
tive, that further explores issues of equity and justice 
in relation to clinical trial recruitment processes is 
warranted. Research on patient and public involve-
ment in clinical trials is conspicuous by its absence 
and should be prioritised to redress some of the pow-
er inequities.
iv. A small group of studies provided nuanced insights 
into organisations that appear to be at opposite ends 
of the ethical debates on clinical trials in India—con-
tract research organisations (CROs) and civil soci-
ety organisations (CSOs).114 115 Although critical of 
ethical malpractice in general, CRO staff were less 
inclined to acknowledge instances of the same in 
their own CROs.115 CSO representatatives were sup-
portive of clinical trials, felt the need to move away 
from pitting Indian and/or public sector clinical tri-
als against foreign and/or private sector clinical trials 
as good versus bad and emphasised the need to focus 
on wider ethical issues that delve beyond simplistic 
procedure- based agendas.
Secondary research
The synthesis of documentary research (B1) corrob-
orated findings from the synthesis of primary research 
and reported: inadequacies in informed consent docu-
mentation, increased workload for ethics committees 
particularly after the 2013 regulatory changes, mismatch 
between clinical trials and India’s disease burden, lack 
of uniformity in compensation mechanisms and subop-
timal clinical trial reporting practices in Indian jour-
nals.64 66 71 74 119 124 125 139 141 The use of Western readability 
tests for written information provided in India62 86 needs 
addressing with the development of readability tests in 
Indian languages. Similarly, while studies on journal 
reporting practices have focused on the reporting of 
ethical approval and informed consent, future studies 
could investigate reporting practices in relation to ques-
tionnaire surveys (given their frequent use and methodo-
logical/reporting limitations as indicated earlier).
Consultation exercise
Nine of the 10 individuals approached agreed to partic-
ipate in the consultation exercise (virtual conferencing 
group: n=7, one meeting, 1 hour 30 min; telephone: n=1; 
email: n=1). The consultation group’s recommendations 
and actions taken were grouped into five key areas as 
summarised in table 4 (detailed in online supplemental 
file 5).
dIsCussIon
We carried out a scoping review and narrative synthesis 
of the empirical literature on ethical issues in relation 
to clinical trials/research in India. We developed an 
evidence map of 80 studies and synthesised the find-
ings narratively, revealing a wide range of topics investi-
gated and the gaps that exist, with key insights from the 
consultation group. We found that some topics and popu-
lations were more favoured than others—the literature 
was heavily focused on ‘knowledge’ assessments of partic-
ipants from lay/professional groups on various topics; 
ethics committees were examined from multiple angles 
while also being the source of data in many studies and 
healthcare students were often research participants. On 
the other hand, studies that investigated the recruitment- 
informed consent process, models of informed consent 
tailored to the Indian context and issues such as equity 
and justice in the context of clinical trials/research were 
far fewer in number or absent.
To our knowledge, this is the first systematic scoping 
review that focuses on empirical research on the ethical 
aspects of clinical trials/research in one country. System-
atic reviews on related aspects (eg, willingness to partic-
ipate) have tended to combine LMICs together44 or 
included people living in India with those of Indian 
origin living in other countries.45
Our findings indicated that the volume of literature 
on a given topic was not associated with whether or not it 
allowed the development of a cohesive synthesis on the 
topic. We found it challenging to develop a lucid picture 
of some frequently researched areas such as knowledge 
on clinical trials/research and research ethics. Given 
the diversity and scale of the population in India, this 
could be a reflection of reality, but the numerous meth-
odological limitations and reporting variations, partic-
ularly among questionnaire surveys, made it difficult 
to identify commonalities that may exist. By contrast, 
although only a small number of studies focused on the 
wider ethical issues, they provided valuable insights into 
the workings of the clinical trials/research industry. 
This may also be because the former group of studies, 
primarily questionnaire surveys, were likely aiming for 
breadth but were often compromised methodologi-
cally, while the explorations of wider ethical issues were 
more amenable to qualitative research and successfully 
provided the depth that was warranted in intense and 
nuanced debates.
Research gaps were identified on topics that need to be 
researched (when limited or missing from current litera-
ture) as well as topics that need to be ‘better’ researched 
(when present in literature but requiring methodolog-
ical/reporting improvements). Given that question-
naire surveys (particularly those exploring knowledge) 
were the predominant method used, methodological 
research on developing and validating culturally rele-
vant survey tools and minimum journal reporting stan-
dards for surveys would be crucial, drawing from existing 
guidelines.144–146 Small- scale, single- centre surveys may 
be useful to inform local practice, but consistent use of 
validated measures and standardised reporting practices 
are needed to contribute to national policy and practice. 
Calls to ensure inclusion of research ethics and clinical 
trials education in the curriculum of healthcare students 
would be bolstered if research can establish and evaluate 
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Table 4 Recommendations from the consultation group and actions taken
Area Recommendations Action
1. Improving the 
manuscript
 ► Change title to better reflect the scope of the review.
 ► Ensure better acknowledgement of the rich bioethics literature 
and lack of grey literature in the review.
 ► Incorporate a reflexive section on the authors.
 ► Emphasise the value of qualitative research in addressing key 
research gaps.
Reflexive note in online 
supplemental file 5; others 
incorporated in manuscript.
2. Additional analysis 
and missed literature
 ► Consider impact of the 2013 regulatory changes.
 ► Consider impact of studies’ funder/sponsor on the research 
landscape.
 ► Examine four missed articles for inclusion.
 ► Additional analysis undertaken 
(data extracted for year of data 
collection and funder).
 ► One article met inclusion 
criteria and was included; 
others, where relevant, have 
been mentioned in methods/
discussion.
3. Research gaps There is insufficient empirical information on:
 ► Informed consent/assent processes for children in clinical trials/
research.
 ► Models of informed consent to suit multiple contexts.
 ► Issues of equity and social justice in relation to clinical trials.
 ► Doctor- recruiter dual role and the arising conflicts of interest.
 ► Regulatory processes.
 ► Academic trials conducted in medical institutions and vaccine 
trials.
 ► Therapeutic misconception.
 ► Questionnaire validation processes.
These gaps have either been 
highlighted separately within the 
review or incorporated within 
existing gaps.
4. Reasons for paucity 
of research
 ► Lack of funding initiatives to carry out nested studies within 
clinical trials and related methodological work is a major 
obstacle for researchers in India.
 ► Not all ethical issues are ‘researchable’ and are sometimes 
better captured through bioethics literature.
Incorporated in discussion.
5. Concerns Most concerns expressed were in relation to ethics committees:
 ► Lack of awareness of principles underpinning clinical research 
and good clinical practice guidelines among committee 
members.
 ► Non- trial study designs encouraged by committees to avoid 
institutional liability for serious adverse events in clinical trials.
 ► Excessive workloads and undeclared roles and conflicts of 
interests among members.
Noted here as this is a reflection 
of the large proportion of studies 
on ethics committees.
The direct impact of the 2013 regulatory changes 
on the research landscape are unclear in this review. A 
few studies investigated professionals’ perceptions of 
regulatory changes,76 89 acceptability and impact of new 
measures such as the AV recording of consent72 78 79 and 
the impact of changes on ethics committees66 106 (latter is 
examined in- depth in an excluded literature review147). 
It would have been useful to further examine the 
review findings through the prism of the landmark 
2013 regulatory changes, but with a third of the studies 
not reporting the year of data collection, this was not 
feasible. It is also important to interpret the findings in 
light of the continually evolving regulatory landscape 
in India, with the most recent changes introduced in 
March 2019 (NDCT Rules).19 For instance, some studies 
raised concerns in relation to the conflicts of interest 
that compromise the independence of ethics committee 
members and the hierarchy between medical and non- 
medical (lay) members of ethics committees, stemming 
partly from issues such as lack of adequate training for 
lay members.92 108 133 With the NDCT Rules now requiring 
50% of members to not be affiliated to the institution in 
which the committee is based and necessitating manda-
tory training for ethics committee members,148 future 
studies can investigate if this has redressed some of the 
concerns around the independence of ethics commit-
tees and the power imbalances within. Similarly, Indian 
regulations on compensation for trial- related injuries 
are acknowledged as comprehensive and having unique 
features (eg, the compensation for injuries not related 
to research),149 but it would be crucial to study the chal-
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The views expressed by some participants (and authors) 
of studies in this review that there was an excessive focus on 
the proceduralism of informed consent is conceivably true 
in practice and appears well documented,67 90 101 121 yet the 
informed consent process was grossly under- researched. 
Given the breaches of good practice reported in the past 
and the routine AV recording of the informed consent 
interaction, it is notable that only one study83 was conducted 
using this resource. It is unclear if the challenges in under-
taking, storing and retrieving AV recordings150 151 has a role 
in their underutilisation for research purposes or if this is 
due to regulatory restrictions. Opening the black box of the 
informed consent process in future qualitative research can 
help optimise comprehension of participants, communica-
tion of complex trial- related terminology in local languages 
and identify aspects of the doctor- patient interaction that 
contribute towards therapeutic misconception.
Given the lack of established benchmarks for what consti-
tutes optimal information provision for potential clinical trial 
participants in India or in the West,152 researchers could also 
establish core information sets (information of core impor-
tance to convey to patients, drawing from empirical evidence 
and consensus building approaches.153 Patient and public 
involvement would need to be a central component in such 
efforts. Interventions to identify informed consent models 
that are suited to the Indian context (community- family 
based and/or Western- individual autonomy based) and to 
specific situations (eg, industry- led and investigator- led trials) 
are warranted.
It would also be useful to critically consider the topics, 
populations and methods that we, as researchers, choose 
to investigate and employ in future studies—for instance, 
(a) whether the ease of access to healthcare students and 
ethics committee members and/or its documentation 
justifies them being frequently researched, especially when 
they are so unrepresentative of participants in trials or (b) 
whether assessing comprehension of informed consent 
information is meaningful without assessing the quality of 
written and/or verbal information provision that preceeded 
it. Future research could also address the lack of read-
ability tests in Indian languages, develop interventions to 
improve ethics committee functioning by overcoming some 
of the identified barriers and curtail the excessive focus on 
‘knowledge’ to redirect efforts on the larger ethical issues 
to tackle the inequities and imbalances in the clinical trial 
industry.90 92 105 112 114 115 121 127 128 However, if knowledge 
assessments were to be undertaken, it would be prudent to 
consider what constitutes optimal understanding among 
research participants152 and whether the outcome of any 
knowledge assessments can be used to improve the informed 
consent process or the comprehension of participants locally. 
The suitability of interventions employed in high- income 
countries to improve participant understanding in informed 
consent for research154 155 needs to be carefully assessed for 
India. Qualitative research methods, underused in the range 
of topics covered in this review, are best suited to investigate 
the larger issues that require depth of understanding rather 
than breadth.
The consultation exercise with key stakeholders in 
India was instrumental in contextualising this scoping 
review and identifying missed research priorities. A key 
structural constraint identified in the consultation exer-
cise and evident in the dataset was that most studies were 
conducted with no to limited external funding. Calling for 
high- quality studies that span a range of topics to fill the 
identified gaps would be misguided without appropriate 
funding mechanisms. Initiatives such as the Medical 
Research Council’s trials methodology hubs across the UK 
have been instrumental in improving clinical trial design, 
conduct and reporting (eg, see final report of trials meth-
odology research carried out over 4 years, 2014–2018, in 
one of the hubs156), with subsequent provisions for initi-
ating trials methodology projects in LMICs.157 It is time 
for international/national funding agencies to consider 
establishing similar methodology hubs led by researchers 
in India, with a focus on the ethical conduct of clinical 
trials. It would be important, however, to ensure that 
in our pursuit of empirical evidence, we do not down-
play the vital role played by other forms of evidence and 
catalysts for change, given that not all ethical issues are 
amenable to being researched.
limitations
Despite our best efforts, we may have missed some rele-
vant journal articles and studies included in books. 
However, if missed articles reflected the patterns of 
published research included in this review, it is likely 
that they would not substantially alter our synthesis and 
conclusions. A decision to only include peer- reviewed 
research also meant we did not seek out grey/unpub-
lished literature158 159 (although condensed publications 
from them, if any, are included103). Some of the topics 
we excluded may have helped contexualise our findings. 
For instance, we included studies on research ethics but 
excluded those on medical/clinical ethics—an associ-
ated topic of interest that requires a separate review.
While the review has helped underline the gaps in the 
existing literature, it is not exhaustive and cannot claim 
to have identified all gaps. It also cannot prioritise the 
identified gaps in a meaningful way and is limited in iden-
tifying key topics that are completely absent or of impor-
tance to key stakeholders. Designing and conducting 
the review with the input of researchers in India from 
conception stages may have resulted in a different focus 
and outcome. Our intention was that the critical input 
of key stakeholders at the consultation phase helped 
focus the review and overcome some of the shortcom-
ings. A locally led priority- setting exercise, informed by 
this review, to determine pressing concerns that warrant 
empirical investigation would be an ideal next step.
ConClusIon
This systematic scoping review is the first attempt at 
summarising peer- reviewed empirical research on topics 
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The review demonstrates that while a wide range of 
topics have been studied in India, the focus is largely on 
assessing knowledge levels across different population 
groups. This is a useful starting point, but fundamental 
questions remain unanswered about the recruitment and 
informed consent process, such as the doctor- patient 
interaction, and the larger issues of equity and justice 
that dominate the clinical trials/research landscape.
The evidence map and narrative synthesis are meant 
to be a starting point for discussions on future research 
directions, to be used in ways that benefit the research 
community and patient population and contribute 
towards the ongoing efforts within India to improve 
the clinical trials/research ecosystem. A priority- setting 
exercise that could be informed by this review, led by 
researchers in India, would be an ideal next step, along-
side funding mechanisms that support researchers based 
in India to undertake research in priority areas in clinical 
trials/research methodology and ethics.
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Supplementary file 1: Figure - Clinical trials approved in India by year and the evolution of research on 
the ethics of clinical trials in India mapped against key regulatory developments 
 
 
Source: Data on number of trials approved by CDSCO (Central Drugs Standard Control Organisation) is taken from 







































































Supreme Court halts approval of new clinical trials
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Supplementary file 3: Inclusion criteria for identification of eligible studies 
Setting India (other South Asian countries included in 
search, but not in any further steps reported) 
Population Any stakeholder groups 
• Lay – patients/patients’ guardians, 
public, CT/cohort study participants; 
• Professional – healthcare/research 
faculty, students or practitioners, 
members/staff of ethics committees or 
regulatory/governmental agencies 
• Other – relevant documents  
Phenomenon of interest Any ethical aspects of conducting clinical 
trials/research in India (e.g. informed consent, 
scientific misconduct, research governance, 
ethics committees and approvals, good clinical 
practice) 
Study design Primary/secondary research of any design 
conducted on human participants (including 
observational, experimental, quasi-
experimental, randomised controlled trials, 
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Supplementary file 4: Medline search strategy 
Database: Ovid MEDLINE(R) Epub Ahead of Print, In-Process & Other Non-Indexed Citations, Ovid MEDLINE(R) 
Daily and Ovid MEDLINE(R) <1946 to Present> 
Search Strategy: 
-------------------------------------------------------------------------------- 
1     exp Informed Consent/ (39822) 
2     consent*.tw. (66248) 
3     (informed adj2 (decision* or choice*)).tw. (9675) 
4     exp Comprehension/ (11748) 
5     exp Awareness/ (18083) 
6     exp bioethical issues/ or exp bioethics/ or exp complicity/ or exp "conflict of interest"/ or exp ethics 
committees/ or exp ethics, institutional/ or exp ethics, professional/ or exp ethics, research/ or exp professional 
misconduct/ (106864) 
7     scientific misconduct.tw. (863) 
8     therapeutic misconception.tw. (216) 
9     exp Disclosure/es, lj [Ethics, Legislation & Jurisprudence] (4428) 
10     disclos*.tw. (70367) 
11     research governance.tw. (246) 
12     good clinical practice.tw. (1424) 
13     exp Confidentiality/ (50771) 
14     *Health Knowledge, Attitudes, Practice/ or *patient education as topic/ (86839) 
15     ((understand* or knowledge or perception* or comprehend* or comprehension or awareness) adj12 
(barrier* or research or study or studies or trial or trials)).tw. (292135) 
16     (information adj3 (patient* or volunteer* or participant* or recruit or recruits) adj3 (study or studies or 
research or trial or trials)).tw. (1179) 
17     or/1-16 (661221) 
18     exp Clinical Trial/ (831342) 
19     exp Clinical Trials as Topic/ (322063) 
20     exp drug approval/ or exp drug evaluation/ or exp feasibility studies/ or exp pilot projects/ (217419) 
21     exp Human Experimentation/ (12631) 
22     exp Research Subjects/ (15759) 
23     ((participa* or tak* part or enrol* or volunteer* or recruit* or subject*) adj7 (trial or trials or research or 
study or studies)).tw. (552279) 
24     ((patient* or candidate*) adj7 (trial or trials or research or study or studies) adj7 (choose* or chosen or 
choice* or select*)).tw. (20782) 
25     (exp Patient Participation/ or *patient selection/ or *volunteers/ or *health personnel/ or *research 
personnel/) and (trial or trials or study or studies or research).tw. (32320) 
26     researcher subject relations/ (1086) 
27     *drug industry/ (19424) 
28     or/18-27 (1709573) 
29     exp bangladesh/ or exp bhutan/ or exp india/ or exp nepal/ or exp pakistan/ or exp sri lanka/ (126661) 
30     (bangladesh or bhutan or india or nepal or pakistan or sri lanka).tw. (112390) 
31     exp Developing Countries/ (71257) 
32     exp Contract Services/ (12492) 
33     outsour*.tw. (1525) 
34     contract research organi#ation.tw. (76) 
35     or/29-34 (243873) 
36     17 and 28 and 35 (3178) 
37     letter/ (992989) 
38     editorial/ (452191) 
39     news/ (186037) 
40     exp historical article/ (387093) 
41     Anecdotes as topic/ (4934) 
42     comment/ (705965) 
43     (letter or comment*).ti. (127313) 
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44     or/37-43 (2228855) 
45     36 not 44 (2827) 
46     exp animals/ not humans/ (4581034) 
47     exp Animals, Laboratory/ (836666) 
48     exp Animal Experimentation/ (8778) 
49     exp Models, Animal/ (516385) 
50     exp rodentia/ (3100283) 
51     (rat or rats or mouse or mice or rodent*).ti. (1315778) 
52     or/46-51 (5412057) 
53     45 not 52 (2811) 
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Supplementary file 5 
A. Members of the consultation group 
Names (in alphabetical order) Role and Organisation Method of 
consultation  
1. Dr Amar Jesani Co-founder of the Forum for Medical Ethics Society; Editor Indian Journal of Medical Ethics; Faculty 
member, Centre for Ethics, Yenepoya University, Mangalore, India 
Virtual group meeting* 
2. Dr Anant Bhan Researcher in Global health and bioethics; Adjunct Professor, Centre for Ethics, Yenepoya University, 
Mangalore, India; Former President, International Association of Bioethics; Lead, Sangath-Bhopal, India 
Virtual group meeting 
3. Professor Gagandeep Kang Professor of Microbiology, Wellcome Trust Research Laboratory, Division of Gastrointestinal Sciences, 
Christian Medical College, Vellore, India 
Virtual group meeting 
4. Dr Manjulika Vaz Lecturer, Health and Humanities, St. John’s Medical College, Bangalore, India Virtual group meeting 
5. Professor Nithya Gogtay Professor and Head, Department of Clinical Pharmacology, Seth GS Medical College and King Edward 
Memorial Hospital, Mumbai, India 
Telephone 
6. Dr Rashmi Rodrigues Associate Professor, Department of Community Health, St. John’s Medical College, Bangalore, India Virtual group meeting 
7. Ms Sarojini Nadimpally Executive Director, SAMA Resource group for women and health, New Delhi, India Virtual group meeting 
8. Professor Urmila Thatte Emeritus Professor, Department of Clinical Pharmacology, Seth GS Medical College and King Edward 
Memorial Hospital, Mumbai, India 
Virtual group meeting 
9. Dr Vijay Gopichandran Assistant Professor, Community Medicine, ESIC Medical College, Chennai, India Email 
* The virtual group meeting was held on October 23rd, 2020 
B. Reflexive note on the systematic scoping review’s authors: The authors of this paper are qualitative researchers (SP, JW, LR, NM, ARe, JD), systematic reviewers (PD, 
AR), bioethicists (JI, RH, SS) and clinician-researchers (JR, JB). SP was born, raised and educated first in India and then in the UK, with brief clinical work experience in 
India and research experience primarily in the UK. JR and SS have carried out research in India. All other authors primarily conduct research in the UK.  
Amongst the authors, SP, JI, JR and JD and amongst the consultation group, AJ, AB, NG, SN and UT are involved in a recently-funded feasibility study (MRC-NIHR Trials 
Methodology Research Partnership global health pump-priming grant) on optimising informed consent in clinical trials in India, as co-applicants, collaborators or advisory 
panel members. 
C. Summary of key recommendations from the consultation exercise 
 Recommendations, explanations and current concerns raised by the consultation group and the actions taken thereof in the manuscript 
1. Improving the 
manuscript 
• Title: Previous title (‘Ethical issues in clinical trials in India: a systematic scoping review and narrative synthesis to map the quantitative and 
qualitative evidence and identify research priorities’) was considered problematic as it suggested that the review was identifying ethical issues 
in clinical trials in India, which was not the aim of the authors. Also, the review was broad and included ‘clinical research and clinical trials’ but 
the title only mentioned ‘clinical trials’. Action: Title was changed to ‘What empirical research has been undertaken on the ethics of clinical 
research in India? A systematic scoping review and narrative synthesis to map the evidence.’ 
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• Bioethics literature: Ensure better acknowledgement of the bioethics literature that includes reflective, narrative and philosophical debates, 
as well as case studies of ethical misconduct, which have not been covered in this scoping review, but have been instrumental in changing the 
regulatory landscape in India. Action: Acknowledged in the introduction. 
• Grey literature: Acknowledge limitations of not including grey literature, including studies that may have been reported in books. Action: 
Mentioned in the limitations. 
• Reflexivity: Include a note on reflexivity to ensure lead author’s views regarding own background as expressed at the meeting are presented 
to the readers. Action: Included above in this supplement.  
• Qualitative research: The role of qualitative research in providing rich empirical evidence to address some of the gaps needs to be 











• Impact of 2013 regulatory changes: Consider the impact of the regulatory changes in relation to ethics committees (i.e. to examine if the 
regulatory changes made a difference to how committees operated before and after 2013) and if there are any significant changes in the 
nature/type of studies in the scoping review dataset or in the findings more generally before and after 2013. Action: To facilitate this, 
additional analysis undertaken involved extracting the year of data collection from studies, but this demonstrated that a large proportion of 
studies did not report the year of data collection; this has now been included in the results and limitations sections. A review paper (excluded 
from this scoping review) that describes the impact of the 2013 regulatory changes on ethics committees in detail147 has been included in the 
discussion section of this scoping review. 
• Study funder/sponsor: Consider whether it is possible to examine the studies based on who funded/sponsored the study, as the type of 
studies conducted or the issues explored may vary based on whether sponsored by academic centres or not. Action: Additional analyses 
involved extracting and analysing each paper’s corresponding author’s institution (academic or not), declarations of source of funding and 
conflicts of interest – included in the results and discussion sections. 
Literature 
• Published research:  
a. A qualitative study on ethical issues in the recruitment of healthy volunteers was highlighted as missing from the scoping review. Action:  
This has now been included in the manuscript results.140 
b. Some studies that report on the Clinical Trials Registry India data were highlighted during the consultation exercise. These provide 
valuable information but audits of the Clinical Trials Registry of India were excluded where they reported the number of trials registered 
per year40 or highlighted the deficiencies in the data41 (and included if they were linked to an ethical issue139,141). Action: This has now 
been further clarified in the methods.  
• Grey literature: Two studies undertaken by SAMA, New Delhi were mentioned during the consultation exercise and later sent to the scoping 
review lead (an unpublished comparative study examining compensation mechanisms in seven countries including India158 and a full 
unpublished report159 of a published and included study.103 Action: These have been mentioned in the limitations section. 
3. Research gaps • Children in RCTs: There is a notion that parents would be less inclined to allow their children to participate, yet experience on the ground 
suggests that parents are willing to allow their children to participate. Research questions to consider: What drives parents to allow children 
to participate in trials? What are the issues in the consenting process? How is assent taken care of? Action: Informed consent/assent in 
relation to children’s participation in clinical research has been included as a research gap. 
• Informed consent:  
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o It is unclear how written consent is operationalised in a country like India where a large proportion of the population is illiterate or 
not literate in the language of the consent form. Research questions to consider: How is written consent obtained in the context of 
multiple languages, illiteracy and healthy literacy in India? Does picture-based informed consent work better than video consent? 
Action: Expanded section on models of informed consent in gaps identified. 
o There is a need to develop models of informed consent that are based on communitarian models suited to the Indian context rather 
than the Western libertarian/autonomy models that currently inform our regulations/guidelines. Action: This has been further 
emphasised in the review. 
• Recruitment process: There is a need to develop a sound empirical holistic understanding of the entire continuum of the recruitment process, 
that takes into account issues of equity and fairness as well as social determinants such as gender, poverty, caste and class and their 
intersectionality. Most of the clinical trial recruitment happens from the hospitals where the health care providers are themselves the 
researchers; there exists a strong conflict of interest, which needs to be explored. Action: Further emphasised in the review. 
• Regulatory processes: There is a lack of empirical evaluations of the regulatory processes (e.g. number of trial applications submitted for 
approval per year, the numbers approved and disapproved, and reasons for the same). Action: Included as a gap in the review. 
• Ethics of academic clinical trials within medical institutions: Many academic clinical trials happen in medical institutions, including those 
conducted by post-graduate residents, but they are rarely researched and scrutinized. Action: Student-led clinical trials included in gaps.  
• Vaccine trial acceptability: There is little empirical evidence as to how vaccine trials are perceived by people and the ethical consideration that 
inform vaccine developers. Action: Included within gaps in the review. 
• Therapeutic misconception: Most trial participants experience therapeutic misconception at some level. There is a need to better understand 
this phenomenon. Action: Further emphasised in review. 
• Validated questionnaires: There is a need for cross-cultural adaptation (as opposed to translation) of validated questionnaires/tools from 
other countries, which is sometimes not allowed. For instance, in a study to evaluate osteoarthritis with patient-reported outcome measures, 
a validated questionnaire asked if the patient can put on and take off stockings, which is not relevant in the Indian context; when asked if that 
can be changed to sitting or getting up from an Indian toilet, the request was refused. It is likely that similar issues exist for questionnaires 
used in studies in this review. Action: Included as a gap in the review.  
4. Explanations 
for some of the 
findings 
• Reasons for paucity of RCTs (and nested RCTs or other types of nested studies) in the dataset: Systematic empirical research requires financial 
support for academics, which is not easily available for researchers in India. Most researchers are expected to carry out research alongside 
their usual clinical or other duties, and under those circumstances, it is difficult to do research that goes beyond explorations of knowledge 
and perceptions. Funding and resource constraints mean that although a number of researchers, including those working in the rural areas, 
are interested in conducting empirical work in relation to informed consent and other ethical issues, their interests often stop at ideation. 
Many research groups, especially in academic medical centres and government medical colleges, have had to avoid clinical trials as they 
would be liable to pay compensation for serious adverse events, which they do not have allocated funds for. Drawing from personal 
experiences, ethics committees have been known to ask investigators to redesign their study, such that it is not a clinical trial, as not many 
institutions have the funds to provide compensation if necessary. Action: Need for funding emphasised in the discussion. 
• Some ethical issues are simply not ‘researchable’ – for instance, corruption and exploitation are difficult to research, but are well captured in 
the bioethics literature. Action: Acknowledgement of the same in the discussion/conclusion. 
5. Concerns • Ethics committees: Key concerns expressed were in relation to ethics committees, in line with the large number of studies on the same.  
Concerns revolved around the following issues: 
BMJ Publishing Group Limited (BMJ) disclaims all liability and responsibility arising from any reliance
Supplemental material placed on this supplemental material which has been supplied by the author(s) BMJ Global Health
 doi: 10.1136/bmjgh-2020-004729:e004729. 6 2021;BMJ Global Health, et al. Paramasivan S
4 
 
o Lack of awareness among ethics committee members regarding good clinical practice guidelines and basic principles underpinning 
clinical research despite training provision for committee members over many years, making it challenging to assess the nuances 
related to clinical trials regarding risk minimisation or participant protection. With this being the case in trained ethics committees, 
there was concern about what may transpire in the case of ethics committees in more remote locations functioning without training. 
o Ethics committees sometimes request investigators to opt for non-trial designs, to avoid institutional liability for compensation if 
necessary (as outlined in section above). 
o Absence of declaration of roles and conflicts of interest by ethics committee members. 
o Increased workload for ethics committee members, which impedes their ability to examine all the relevant aspects in detail. 
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Supplementary file 6: Research aims, settings and methods of individual studies 
Study Research aims and setting Research methods 
A. Primary research: Knowledge (or awareness/comprehension), attitudes (or perceptions), practice (or behaviour) 
• Studies on the comprehension of the informed consent form and/or verbal information provision 
Arora et al, 201162 To assess comprehension of ICF/IC among participants in a first-in-human study of a novel drug in healthy 
male volunteers; Chandigarh, India 
Questionnaire survey; n=50 
Bhansali et al, 
200965 
To assess comprehension of ICF/IC among patients invited to participate in a phase 3 multi-centric trial of a 
novel lipid lowering agent; Chandigarh, India 
Questionnaire survey; n=42 
Figer et al, 201778 To assess comprehension of ICF/IC among participants in a Phase 2/3 rabies monoclonal antibody trial, 
before and after introduction of mandatory audio-visual recording of IC process in 2013; Mumbai, 
Maharashtra, India  
Questionnaire survey; n=38 
George et al, 201880 To assess comprehension of ICF/IC in hypothetical RCTs among adult in-patients with non-organic 
psychiatric disorders and among their key relatives; Vellore, Tamil Nadu, India 
Questionnaire survey; n=32 (14 patients; 18 relatives) 
Gota et al, 201882 To assess comprehension of ICF/IC among patients enrolled in Phase 1, 2 or 3 interventional studies; 
Mumbai, Maharashtra, India 
Questionnaire survey; n=200 
Joglekar et al, 
201387 
To assess comprehension of ICF/IC among participants in a cohort study aimed at estimating HIV incidence 
in a high-risk population; Pune, Maharashtra, India 
Questionnaire survey; n=1334 
Kamath et al, 
201491 
To assess comprehension of ICF/IC among medical students invited to participate in a hypothetical anti-
malarial drug; South India 
Questionnaire survey; n=155 
Nambiar et al, 
2012104 
To assess comprehension of ICF/IC among nursing trainees participating in a tuberculosis exposure and 
latency cohort study; Vellore, Tamil Nadu, India 
Questionnaire survey; n=138 
Sarkar et al, 2009117 To assess comprehension and recall of ICF/IC among parents/guardians of a birth cohort of children from 
urban slums participating in a diarrhoeal surveillance study; Vellore, Tamil Nadu, India  
Questionnaire survey; n=368 
Sarkar et al, 2010116 To assess comprehension of ICF/IC among parents of children from rural pre-schools participating in an 
RCT of nutritional supplementation, randomised to receive group or individual counselling for IC; 
Kaniyambadi, Vellore, Tamil Nadu, India 
RCT employing questionnaire survey; n=118 (from 16 
rural pre-schools) 
• Studies on Knowledge, Attitudes, Practices in relation to clinical trials/research, research ethics, ethics committees 
Bhowmick et al, 
2014130 
To assess knowledge, attitudes and practice of ethics committee functioning among ethics committee 
members; Kolkatta, West Bengal, India 
Questionnaire survey; n=30 (from 10 ethics committees) 
Burt et al, 201369 To study knowledge and perceptions of clinical research among general public; New Delhi, India Questionnaire survey; n=175 (from eight public locations) 
Choudhury et al, 
201675 
To assess knowledge and perceptions of clinical trials among doctors from government medical colleges; 
West Bengal, India 
Questionnaire survey; n=133 (from three medical 
colleges) 
Deolia et al, 201477 To assess knowledge, attitudes and behaviour pertaining to research ethics among dental professionals in 
a private dental institute; South India 
Questionnaire survey; n=213 
Dhodi et al, 2013131 To assess knowledge, attitudes and practices towards clinical research among medical students and 
teachers; Mumbai, Maharashtra, India  
Questionnaire survey; n=395 
Gopinath et al, 
201481 
To assess knowledge and attitudes about research ethics and ethics committees among dental faculty; 
Chennai, Tamil Nadu, India 
Questionnaire survey; n=81 
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Hussain et al, 
2019132 
To assess knowledge, attitudes and practice regarding informed consent process in biomedical research in 
postgraduate medical students in a private medical college; Karnataka, India 
Questionnaire survey, n=114; Group discussions, n=2 
(with 10-12 participants each) 
Londhey et al, 
201597 
To assess awareness of ethics committee composition and functioning among medical teachers; Mumbai, 
Maharashtra, India 
Questionnaire survey; n=180 
Joshi et al, 201288 To explore awareness, perceptions of and attitudes towards participating in clinical trials among general 
public; Pune, Maharashtra, India 
Focus group discussions and interviews; n=24 (7 trial 
participants; 17 non-trial participants) 
Joshi et al, 2013134 To assess awareness, perceptions and attitudes toward clinical trials and their views on methods to create 
awareness among general public; Pune, Maharashtra, India 
Questionnaire survey; n=240 (40 trial participants; 200 
non-trial participants) 
Krishna et al, 
2014140 
To examine the relationship between contract research organisations (CRO) and healthy volunteers and 
the recruitment process in relation to bioavailability and bioequivalent studies; Hyderabad, Telangana, 
India 
Case study of one contract research organisation 
comprising: Interviews (8 CRO staff); group discussions 
(n=50 healthy volunteers); observations of informed 
consent discussions (n=40) 
Mallela et al, 
201598 
To assess knowledge and attitudes about research ethics and ethics committees among dental faculty; 
North India 
Questionnaire survey; n=942 
Meenakumari et al, 
2010100 
To evaluate awareness of clinical trials among pharmacy undergraduate and postgraduate students; 
Manipal, Karnataka, India  
Questionnaire survey; n=102 
Mishra et al, 
2018101 
To examine awareness of ICMR's ethical guidelines, privacy-relation obligations and experiences in 
implementing ethics guidelines among ethics committee members; New Delhi, India  
Interviews; n=19 
Mohammad et al, 
2011135 
To assess knowledge, attitudes and practices of healthcare ethics among medical professionals in a 
government teaching hospital; Aligarh, Uttar Pradesh, India 
Questionnaire survey; n=172 
Nadig et al, 2011102 To assess knowledge, attitudes and practices pertaining to ethics review and ethical guidelines among 
ethics committee members; South India 
Questionnaire survey; n=29 (from 11 ethics committee) 
Ramanaik et al, 
2015112  
To explore knowledge and perceptions of clinical trials (with a focus on HIV vaccine trials) among frontline 
health service providers working with female sex workers and men who have sex with men; Bellary, 
Belgaum, Bangalore in Karnataka, India 
Interviews; n=50 
Reddy et al, 2013137 To assess knowledge and attitudes about research ethics and ethics committees among dental faculty; 
Bhimavaram, Andhra Pradesh, India 
Questionnaire survey; n=100 
Rodrigues et al, 
2013113 
To assess knowledge regarding knowledge regarding research among HIV-infected individuals; Bangalore, 
Karnataka, India 
Questionnaire survey; n=173 
Sridharan et al, 
2016122 
To assess knowledge of clinical trials from semi-urban and rural populations in India; India Questionnaire survey; n=400 
Vittalrao et al, 
2018129 
To assess awareness of clinical trials among medical undergraduate students; Manipal, Karnataka, India Questionnaire survey; n=257 
Vyas et al, 2019138 To assess knowledge, attitudes and practices regarding informed consent for research purposes among 
postgraduate resident doctors; Mumbai, Maharashtra, India 
Questionnaire survey; n=100 
Thatte et al, 
2009125 
To assess knowledge of compensation clinical trial related injury and among various stakeholders and to 
review policies on the same; India 
Questionnaire survey, n=80 (30 investigators, 23 ethics 
committee members, 27 sponsors); Interviews, n=14 (3 
investigators, 6 ethics committee members, 5 sponsors); 
Documents, n=119 (informed consent documents)  
A. Primary research: Perceptions, experiences, practices/processes in relation to clinical trials/research, research ethics, ethics committees 
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Bindra et al, 201067 To explore perceptions on research ethics among investigators; India Questionnaire survey; n=29 
Brahme et al, 
200968 
To study the profile and role of ethics committee members in health and research organisations; Pune, 
Maharashtra, India 
Questionnaire survey; n=52 ethics committee members 
from 12 committees 
Chatterjee et al, 
201570 
To assess feasibility of informed consent procedure in an RCT for people with schizophrenia, from the trial, 
research and participant perspectives; Tamil Nadu, Maharashtra and Goa, India 
Focus group discussions, n=6; consent interviews and 
participant feedback on IC process, n=332 
Chauhan et al, 
201572 
To explore acceptability of audio-visual recording of the IC process in a hypothetical study and reasons for 
refusal; Keezhputhupattu, Tamil Nadu, India 
Structured interviews; n=150 
Chenneville et al, 
201673 
To assess perceived capacity of medical school ethics committees through ethics committee members and 
delineate areas for improvement; West India 
Research Ethics Committee Quality Assurance Self-
Assessment Tool filled by member secretaries of two 
ethics committees, n=2; Interviews with committee 
members, n=6 
Davis et al, 201776 To explore perceptions of the 2013 regulatory changes for clinical research among ethics committee 
members; South and West India 
Questionnaire survey; n=25 members from 25 ethics 
committees 
Ganguly et al, 
201679 
To describe the newly introduced audio-visual recording of the IC process for clinical trials and the 
perceptions of investigators and trial participants of the same; Gujarat, India 
Observations of audio-visual recordings of IC process, 
n=5; Interviews, n=8 (3 investigators and 5 trial 
participants) 
Gupta et al, 201883 To examine the audio-visual consent process during a Phase 3 rotavirus vaccine trial in healthy infants and 
parent/guardian participation in the consent process; Chandigarh, India 
Audio-visual recordings of consent process; n=100 
Hate et al, 201584 To examine key stakeholders' perspectives on data sharing in the context of research involving women and 
children; Mumbai, Maharashtra, India 
Interviews, n=22; Focus groups, n=44 in four focus groups 
(researchers, managers, research participants, ethics 
committee members) 
Jadhav et al, 
2013133 
To understand perceptions regarding the ethics of clinical research among clinical research professionals; 
India 
Questionnaire survey; n=34 (27 sponsor/contract 
research organisation staff; 6 ethics committee members; 
1 investigator) 
Kadam et al, 201689 To assess perceptions of the 2013 regulatory changes for clinical research among clinical trial investigators; 
India 
Questionnaire survey; n=73 
Kamat, 201490 To elicit perspectives of stakeholders regarding media representation of their work and ethical issues 
arising from their engagement in clinical trials; Bangalore, Karnataka and Hyderabad, Telangana in India 
Interviews; n=42 (3 sponsors, 7 contract research 
organisation executives, 19 investigators, 13 ethics 
committee members) 
Kandhari et al, 
201392 
To provide insights into the structure and functioning of ethics committees from the perspective of ethics 
committee members; New Delhi, India 
Interviews; n=17 
Nadimpally et al, 
2017103 
To explore perceptions of clinical trials among trial participants and key informants; Gujarat, Maharashtra, 
New Delhi, Andhra Pradesh in India 
Interviews; n=36 
Newman et al, 
2015105 
To elicit perspectives and experiences of key informants involved in community stakeholder engagement 
activities, in the context of previous HIV vaccine trials in four countries, including India; Chennai, Tamil 
Nadu, India 
Interviews, n=93 interviews; Focus groups, n=140 in 21 
focus groups 
Parikh et al, 2011136 To assess the perceptions regarding the clinical drug trial industry among various stakeholders; India Questionnaire survey; n=181 (clinical research 
coordinators/assistants, investigators, managers, 
directors) 
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Patel et al, 2016108 To explore perceptions regarding the ethical review process and performance of ethics committees among 
clinical research professionals; India 
Questionnaire survey; n=385 
Patel et al, 2016109 To understand perceptions regarding ethical standards and issues in clinical trials in Indian among clinical 
research professionals; India 
Questionnaire survey; n=385 
Rajaraman et al, 
2011111 
To assess extent of participation during informed consent process among parents providing consent for 
children's participation in an observational tuberculosis study; Palamaner, Chittoor, Andhra Pradesh, India 
Observation notes on questions asked by parents during 
informed consent process; n=4382 
Sariola et al, 
2015115 
To explore perceptions of contract research organisations' staff regarding changes in the clinical trial 
industry since 1995 and 2005, outsourcing of clinical trials to India and models of collaborations; 
Bangalore, Karnataka; Mumbai, Maharashtra; New Delhi, India  
Interviews; n=25 (clinical research assistants, managers, 
protocol writers, quality assurers, statisticians, CEOs) 
Sariola et al, 
2019114 
To explore the role of civil society organisations, academic and public health researchers and health 
activists in changing the regulations for clinical trials in India; India 
Interviews; n=25 (academic public health and medical 
researchers, health activists) 
Simpson et al, 
2015121 
To identify the tensions that emerge for ethics committee members as the capacity to conduct credible 
ethical review of clinical trials is developed across three countries including India 
Interviews; n=14 ethics committee members from India 
Vaz et al, 2015127 To explore the perceptions, motivations and concerns of the public with respect to participation in clinical 
trials and biobanking-related research; Bangalore, Karnataka, India 
Interviews; n=14 
Vaz et al, 2018128 To understand views on the ethics of biobanking research among ethics committee members and medical 
researchers; Bangalore, Karnataka, India 
Interviews; n=43 (21 ethics committee members and 22 
researchers) 
Vaidya et al, 
2016126 
To investigate if coercion is involved in decision-making of medical undergraduate and postgraduate 
students participating in research; Mumbai, Maharashtra, India 
Questionnaire survey; n=300 
B. Secondary Research: Reviews of documents 
Bavdekar, 200964 To determine the extent to which issues related to the provision of free treatment and compensation for 
research-related injury are addressed in the informed consent documents from protocols submitted to 
ethics committees; Mumbai, Maharashtra, India   
Documentary analysis; n=138 
Bhide et al, 201666 To evaluate the impact of the 2013 regulatory changes on ethics committee structure, review process, 
outcomes and administration; Mumbai, Maharashtra, India 
Documentary analysis 
Chaturvedi et al, 
2017139 
To assess if clinical trials were in line with the health care needs of the country by auditing the clinical trials 
registry of India 
Database analysis (Clinical Trials Registry of India) 
Jadhav et al, 201585 To evaluate completeness of ethics application forms submitted for review to ethics committees; 
Maharashtra, India 
Documentary analysis; n=100 
Jhanwar et al, 
201086 
To assess the ease of readability of translated informed consent forms used in psychiatric clinical trials; 
Varanasi, Uttar Pradesh, India 
Documentary analysis; n=30 
Kundapura et al, 
201395 
To assess compliance of informed consent documents with regulations; Pune, Maharashtra, India Documentary analysis; n=50 
Kuyare et al, 201496 To assess queries raised by ethics committees in uninitiated studies and whether these studies obtained 
ethics approval elsewhere; Mumbai, Maharashtra, India 
Documentary and database analysis; n=219 uninitiated 
studies (minutes of ethics committee meetings) and 
Clinical Trials Registry-India data 
Padhy et al, 2011107 To assess compliance of informed consent documents from protocols submitted to ethics committees in 
relation to the Indian Good Clinical Practice guidelines; New Delhi, India 
Documentary analysis; n=300 
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Patwardhan et al, 
2014110 
To compare the quality and completeness of data and documentation between an investigator-initiated 
trial and an industry-sponsored study; Mumbai, Maharashtra, India 
Documentary analysis and data from 42 patients (28 from 
investigator-initiated trial; 14 from industry-sponsored 
study) 
Selvarajan et al, 
2013141 
To evaluate the trends in clinical trials in India compared to other countries, and make comparisons to 
India’s disease burden 
Database analysis (multiple clinical trial registries) 
Shah et al, 2016118 To check completeness and find errors in application forms submitted to ethics committees; Bhavnagar, 
Gujarat, India 
Documentary analysis; n=100 
Shetty et al, 2012120 To review ethics committee application forms for completeness; Mumbai, Maharashtra, India Documentary analysis; n=445 
Shetty et al, 2012119 To monitor adherence to protocol and the informed consent process through clinical research site visits by 
ethics committee members; Mumbai, Maharashtra 
Documentary analysis; n=7 site monitoring reports 
Marathe et al, 
201899 
To study the payments for participation allowed by ethics committees and reasons for payments; Mumbai, 
Maharashtra, India 
Documentary analysis; n=227 studies (ethics application 
forms, protocols, informed consent documents, 
correspondence of ethics committees with investigators) 
Nishandar et al, 
2019106 
To evaluate status of registered, re-registered and accredited ethics committees in India in relation to 
regulations; India 
Database analysis (Central Drugs Standard Control 
Organization, National Accreditation Board for Hospitals 
and Healthcare Providers, Clinical Trials Registry of India 
and Census data); n=1268 ethics committees 
Taur et al, 2011123 To determine extent to which ethics committees comply with requirements mentioned in guidelines and 
regulations while issuing letters of approval; Mumbai, Maharashtra, India 
Documentary analysis; n=20 (approval letters from 20 
ethics committees) 
B. Secondary Research: Journal articles 
Bavdekar et al, 
200863 
To determine proportion of research manuscripts reporting on ethical clearance and obtaining informed 
consent and/or assent in two paediatric journals published from India 
Documentary analysis; n=132 manuscripts 
Chaturvedi et al, 
200971 
To examine whether informed consent and ethical approval were reported in published psychiatric 
research in one psychiatric journal published from India 
Documentary analysis; n=157 manuscripts 
Chin et al, 201174 To explore how often journal articles reporting HIV research sponsored by a developed country but 
conducted in a developing country mention ethics approval from both countries; four countries including 
India 
Documentary analysis; n=50 manuscripts from India 
Klitzman et al, 
201093 
To explore how often human subject research on HIV reported a funding source and conflict of interest in 
four countries, including India 
Documentary analysis; n=79 manuscripts from India 
Klitzman et al, 
201194 
To investigate how often human subject research on HIV reported on ethical approval in four countries, 
including India 
Documentary analysis; n=79 manuscripts from India 
Tharyan et al, 
2013124 
To evaluate improvements in Indian journals' editorial policies and reporting quality of RCTs and to 
compare with reporting quality of protocols in the Clinical Trials Registry-India 
Documentary analysis; n=67 Indian medical journals; 145 
published trial reports; 768 randomised trials registered 
on the Clinical Trials Registry-India  
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Supplementary file 7: Full report of narrative synthesis (or process) components] 
A.1. Comprehension of the clinical trial/research informed consent form and verbal information provision in a real or hypothetical research study: Lay (and some professional) participants 
Number of studies tagged to topic: 1062,65,78,80,82,87,91,104,116,117 
Methodological aspects and limitations: 
• Comprehension was assessed through questionnaire surveys conducted with sample sizes that were generally small (n < 50)62,65,78,80 to moderate (n = 100 to < 200),82,91,104,116 with two 
larger studies87,117 (n = 1334 and 368).  Most studies, including small-scale, carried out inferential statistics (9/10). 
• Most studies were within a single centre. 62,65,78,80,82,91,104 Some did not mention the time period between information provision and comprehension assessment62,87, with a few conducted 
more than a year78,104 to four years117 after the informed consent interaction.  
• Response categories in tools were not clear/not provided in some studies78,104,116,117, and in others they ranged from multiple-choice questions62,65 to combinations of categorical and 
open-ended questions82,87,91. 
• Method of questionnaire administration (6/10), source(s) for questionnaire content (6/10), and whether questionnaire was piloted/validated (5/10) were sometimes not clear or 
provided.  
• Demographic information such as age, gender and education and/or literacy levels were more often provided (although not always) than religion and indicators of socio-economic status 
such as employment and income. 
Synthesised findings: 
• Lay group studies (n=8): Participants were reported as comprising a majority of those educated to primary level or more,65,117 secondary level or higher,80,82 not completing secondary 
level116 or as mostly literate.78,87 Some studies suggested that lay participants (and/or their relatives) mostly had difficulty understanding or recalling information on the study 
background,62 what is a clinical trial,82 study treatment being unproven yet as the best for their condition,82 the condition under study,117 risks80,87 and benefits78.  Additionally, in RCTs, 
randomisation,65,116 blinding65 and the need for a placebo65 appeared difficult to comprehend.  A few studies reported that more participants were found to understand that they were 
taking part in a research study,87,116 study procedures (e.g. blood samples),87,116 and confidentiality.78,87 Study purpose was reported as both well78 and poorly understood.116,117 
Comprehension on different aspects of autonomy appeared to vary. Some studies indicated that while most participants understood the voluntary nature of participation,87,116,117 a 
nuanced understanding of their rights may be lacking as they did not appear to be aware that they were free to withdraw at any point116,117 or that declining participation would not 
adversely affect their or their children’s regular medical care.116  In contrast, the rights of participants62,78,82,87 (such as alternatives to taking part, access to standard care, declining 
participation or withdrawing)82,87 were reported to be well understood in some studies.  
• Some studies reported that there was no statistically significant variation in comprehension by age,78,82,87 gender78,82,87 (except for risk-related information which was better understood 
by women)87 socio-economic status,78,117 income,65 employment status87 and time taken for consent.78 There was variation in comprehension by literacy reported in a large study87 and no 
variation in a smaller study.78 Similarly, there was variation in comprehension by education in a large study (maternal education)117 and no variation in small to moderate-sized 
studies.62,65,82 One study reported no difference in comprehension between patients who were illiterate and those who were educated (non-college or college).82  
• One RCT that compared group and individual counselling for informed consent did not find a difference in comprehension of key elements between the two groups116 and an 
observational study that compared informed consent comprehension scores before and after the introduction of the mandatory AV recording for the consent process found better 
comprehension after78 (the duration between consent and questionnaire administration was shorter in the AV group). One study reported that comprehension was significantly higher in 
pharmaceutical industry-sponsored trials compared to investigator-initiated trials (which the authors have attributed to the elaborate informed consent forms and the lengthier informed 
consent process in the former).82 In some studies, the comprehension assessment was used to provide further information to participants on the topics in which they had a lower score, 
62,87 with one incorporating a cut-off of comprehension scores > 80% to be eligible for study enrolment (unclear if participants were retested after further information provision). Studies 
did not explore what may constitute optimal understanding or information provision. 
• Professional group studies (n=2): Studies that assessed comprehension in a real cohort study amongst nursing students (undergraduate and postgraduate)104 and a hypothetical clinical 
trial amongst medical students (undergraduate),91 both reported insufficient levels of understanding, although these scores appeared much higher than the scores reported for the lay 
groups. 
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A.2. Knowledge of and attitudes/perceptions to clinical trials/research more generally (not in the context of specific studies):  
i. Lay participants 
Number of studies tagged to topic: 769,88,113,122,127,134,140 
Methodological aspects and limitations: 
• Amongst the four questionnaire surveys, the larger study (n=400)122 used descriptive statistics and the more moderate-sized studies (n ~ 175 to 240)69,113,134 used inferential statistics.  
• Two studies administered the same 20-item questionnaire, with Yes/No and True/False/Not Aware response categories to elicit attitudes/beliefs69,122 that were also reported as 
knowledge or awareness.   
• Aspects such as method of questionnaire administration122, validation/piloting134 and source(s) that informed the content of the questionnaire113 were not mentioned in some studies. 
• Demographic information such as age, gender and educational qualifications of participants were generally provided. 
• Two were qualitative studies (n=24 and 14)88,127 that used interviews and/or focus groups, but one study reported the findings descriptively with numerical presentation of results 
(without an interpretive account).88 Findings from another qualitative study, where knowledge exploration was not the focus, have also been included here (group discussion with 50 
healthy volunteers; other findings from this study have been included in  A5 and A6).140 
Synthesised findings: 
• More than half the participants in three of the questionnaire survey studies were educated to graduate level or more69,122,134 and in the fourth, the majority of participants (72%) had 
had more than 7 years of education (i.e. at least primary level).113 Four studies accessed participants primarily from hospital settings88,113,122,134 and one from public locations.69 
Qualitative studies mostly comprised participants educated to above primary school level127 and to graduate/post-graduate level.88 
• Knowledge: Qualitative studies reported that participants (including graduates) who were taking part in clinical research (bioavailability/bioequivalent studies)140 and those who had not 
previously taken part in CTs88 were unaware of what they were or involved (including study name/purpose; only aware that blood would be drawn from them, they may develop rashes 
or a headache and that they should report other symptoms), that non-English speakers had not heard of the word ‘research’ and were not familiar with the local translations for the 
word127 and that lay participants were generally unaware of the rules and regulations of biomedical research or the role of ethics committees in protecting patient interests.127 The 
proportion of participants who said they had heard of clinical trials or clinical research varied considerably across the questionnaire surveys from ~25%69,134 to  60%.113 On exploring 
what participants knew, some studies reported that knowledge was basic88,113 (i.e. associating clinical trials/research with finding something new) to incorrect among some 
participants.134 Those who had heard of ‘research’ appeared to have positive expectations of it.127  
• Attitudes: Studies reported that lay participants had overall positive attitudes towards clinical research (i.e. that it benefits community, society, humanity69,113,122 and is an important 
step in developing new treatments and advancing medical science69,122,127,134), with some noting that participants’ main areas of concern were around the protection of participant 
confidentiality, compensation for participation and adverse outcomes,69,122 unethical practices in trial conduct127 (such as fudging data, profiteering, using people as guinea pigs), and 
lack of trust in pharmaceutical research.134 Research by academic institutions appeared to be more trusted than those by pharmaceutical companies, with just over half the participants 
in some studies trusting the government to protect the public against unethical research.69,122 
 
ii. Professional participants 
Number of studies tagged to topic: 575,100,112,129,131 
Methodological aspects and limitations: 
• Amongst the four questionnaire surveys, two studies (n=133 and 395) used inferential statistics75,131 and two (n=102 and 257) used descriptive statistics.100,129 
• Two studies used the same questionnaire, but the source(s) used to inform questionnaire content was unclear.100,129 Studies had some explanation of validation/piloting of 
questionnaires used, but some did not explain questionnaire administration clearly.75,100,129 
• Demographic information such as education were usually provided but not gender and age of participants in some instances.100,129 
• Other key information of relevance, i.e., prior clinical trial/research training (curricular or extra-curricular) and experience was usually provided. 
• One qualitative study employed in-depth interviews (n=50).112 
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• Studies were conducted with doctors,75 healthcare students (pharmacology100 and medicine129), a combination of medical students and teachers131 and Frontline Health Service 
Providers112 (FHSPs providing services to female sex workers and men who have sex with men; includes doctors, nurses, counsellors, outreach workers, peer educators, programme 
managers).  
• Knowledge: Studies reported basic level of knowledge of clinical trials/research amongst doctors 75 and medical students and teachers,131 but lack of familiarity with methodological 
aspects and regulatory requirements of clinical trials.131 Knowledge on aspects such as patient confidentiality and rights (e.g. to withdraw after study enrolment and for compensation 
due to study related injury) appeared adequate75, while knowledge on aspects such as guidelines, regulations and regulatory authorities appeared inadequate.75,100,129 The qualitative 
study with FHSPs found that more than half the participants across different educational backgrounds had little or no awareness of what a clinical trial entailed.112 Participants were 
unfamiliar with the English term ‘clinical trial’ as well as the local translation of the term (similar to lay participants above). Those who had some knowledge of the existence of clinical 
trials (usually participants with degree level education), admitted to having limited knowledge and some confused clinical trials with routine medical tests and procedures.112 
• Attitudes: Some studies reported overall positive attitudes to clinical trials/research amongst doctors and medical students/teachers75,131 (such as ‘clinical research is important for the 
progression of medical science’).  Negative attitudes towards pharma or industry-sponsored studies were reported75 (e.g. majority believed that clinical trials carried out for academic 
purposes were more ethical/scientific than industry-sponsored trials, patients were exploited and legislations were inadequate in industry-sponsored trials).  Clinical trials conducted in 
India were not considered of good quality by many131 and there was support for including clinical trials in detail in the undergraduate/postgraduate medical curriculum.75,131 
 
A.3. Knowledge, attitudes/perceptions and practices in relation to research ethics (including informed consent): Professional (and some lay) participants 
Number of studies tagged to topic: 1667,77,81,98,101,103,109,126,127,132,133,135-138 
Methodological aspects and limitations: 
• Of the 12 questionnaire surveys, seven (n=81, 100, 114, 172, 213, 300, 385) stated they used inferential statistics77,81,109,126,132,135,137 (but one was reported entirely descriptively;109 the 
same dataset was used in another article to report on ethics committees and has been included in section E).  Five surveys, including a large one (n=29, 942, 34, 181, 100) used 
descriptive statistics67,98,133,136,138 (the findings from the large survey have been minimally used in the synthesis due to discrepancies across numbers/proportions mentioned in tables, 
results and discussion).98  
• Details that were unclear/not provided included questionnaire administration,67,126,132,138 source(s) used to inform questionnaire development67,98,109,132,133,135-137 and 
validation/piloting.109,132,133,136,137 Three studies used similar questionnaires.81,98,137 It was not always clear if knowledge on the topic was self-reported or objectively assessed.98,135 
Generally, attitudes were better explored and reported on than knowledge.  
• Demographic information such as education, age and gender were usually provided (all133 or some aspects, i.e. age and/or gender, were sometimes not provided67,109,135,136). 
• In some instances, information was unclear/not provided on whether participants had had prior clinical trial/research training67,77,98,126,133,135-138 and experience77,98,133,136.  
• One study was reported as a mixed methods study; the reporting of methods and results were however not clear, including the qualitative aspects, so findings have been used 
minimally in the synthesis.132 In another study, some questions were not framed clearly and some knowledge questions appeared to assess attitudes138. One study was authored by 
employees of a pharmaceutical company67 and two studies by employees of clinical research organisations (CROs).133,136 
• Two qualitative studies employed interviews, one with professional group participants (n=19)101 and another103 with both lay (n=32) and professional participants (numbers not 
available).  Lay participant views from this study103 as well as from another qualitative study127 (methods included in section A2.i.) have also been included in this section on professional 
participants as it covers similar themes. 
 
Synthesised findings: 
• Four studies were conducted with dental professionals (dental faculty only81,98 or with dental students and faculty77,137); one was with medical professionals (medical students and 
faculty);135 and three were with professionals primarily from clinical research organisations/sponsors, but also comprising other stakeholders such as investigators and ethics committee 
members (henceforth referred to as clinical research professionals for simplicity).67,133,136 Of the four studies that focused on informed consent, one was with clinical research 
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professionals109 and three were conducted with medical students.126,132,138 One qualitative study explored ethics committee members’ views on issues such as ethical guidelines.101 A 
further two qualitative studies were primarily with lay participants - focused on clinical trial participants’ experiences of participation103 and on biobanking and biomedical research in 
general127 (the only two lay participant views included in this section). 
• Knowledge:  
o Research ethics: Studies reported that there appeared to be gaps in self-reported knowledge (i.e. where participants where asked if they were familiar/aware of a particular topic 
or not) of research ethics81,137  or poor actual knowledge77 (i.e. when reported as tested/assessed, although unclear what questions were asked) amongst dental professionals.  
o Ethical guidelines: Self-reported knowledge on national/international guidelines for research ethics was noted to be poor among dental98 and medical professionals.135 Ethics 
committee members (from 11 committees) in a qualitative study were generally found to be aware of national ethical guidelines (but not international).101   
o Informed consent: One study reported that knowledge of informed consent was good as all participants (medical students) knew that informed consent: was not only verbal 
consent, should include information that it is a research study, includes patient autonomy to withdraw at any time, is mandatory in prospective studies and should not be 
obtained with undue inducement. Most medical students were also noted as being aware that informed consent includes aspects such as study duration, information on 
risks/benefits of participation, statements on confidentiality/privacy and is mandatory in observational surveys.138 In general, studies reported that medical students had good 
knowledge of informed consent but poor attitudes and practices in relation to the same.132,138 In a qualitative study with clinical trial participants (lay group), some appeared 
confused between the signing of the informed consent form and filling of the questionnaire for the trial.103 In another qualitative study with lay participants, to most respondents, 
‘to consent’ meant ‘to agree’ and that this was done by signing (however, this was in general seen as providing protection to the doctor/researcher/hospital than the patients).127 
• Attitudes:  
o Research conduct: There appeared to be some support, amongst dental professionals, for fabricating data to improve research outcomes if it did not harm patients (ranging from 
12% to 44%).81,98,137 A fifth of resident doctors appeared willing to undertake research that was rejected by ethics committee.135 There was all round support for the need to 
protect confidentiality of participant data and to take measures to prevent accidental exposure of patient data.81,98,137   
o Informed consent: Some ethics committee members felt that the informed consent form was merely a tool to obtain signatures, it was often not read to patients and not in local 
languages.101 Similarly, more than half the clinical research professionals felt that the informed consent process does not truly inform patients and is focused on legal 
compliance.67 More than 90% of dental professionals were in favour of informing patients of the risks and benefits of research,81,98,137 always including the patient’s signature as 
part of informed written consent, seeking informed consent when involving patients with invasive procedures and for the use of biological samples (but lesser support in relation 
to blood samples, 78% and 44%).98,137 Most post-graduate medical students (> 80%) believed that informed consent should be explained in the local language, be obtained before 
the start of research work and patients should be allowed to withdraw after signing informed consent; fewer (66%) believed that a witness was absolutely necessary during 
informed consent.138 Majority (> 80%) of clinical research professionals believed that participants were offered the opportunity to ask questions, were able to refuse 
participation133 and had full understanding that there was no compulsion to participate,67 although very few from the same group believed that patients were truly autonomous.67 
Most clinical research professionals in another study believed participants did not have full understanding that there was no compulsion to participate109.  More than half of 
clinical research professionals believed participant rights and alternative treatment options were explained during the informed consent process and about half felt patients were 
adequately informed about trial participation and informed of risks,133 but most clinical research professionals in another study believed participants were not properly informed 
of risks.109 Many clinical research professionals believed that the informed consent process should be monitored by ethics committees or patient research advocates.109  
o Informed consent forms: Most clinical research professionals had concerns about information on funding on informed consent forms, along with information provided on study 
purpose, possible risks/benefits and right to withdraw; they believed forms should be simplified and include pictorial images.109   
o Research ethics education: Most dental professionals were in support of research ethics education for postgraduate students, investigators and ethics committee members.81,98,137  
o Clinical trial drug industry:  Most clinical research professionals believed that the industry in India is growing, but that India is not utilising its full potential and delays in regulatory 
approvals were a key hurdle to the growth of the clinical trial industry in India (lack of trained investigators/site staff, unethical practices and public awareness also selected as 
hurdles by many, but lack of patient population and increasing costs of clinical research in India were not).136  
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• Practices: One study reported ‘unsatisfactory’ behaviour in relation to how frequently dental professionals used scientific journals/internet regarding research ethics, whether they 
maintained accurate patient records for research and whether they attended training programmes in research ethics.77   
o Informed consent: Majority of medical professionals had obtained written informed consent during research.135,138 Proportion who did this in the local language varied (< 50%135 
to > 80%138).  The majority (> 80%) of medical professionals in one study stated that they obtained the signature of an impartial witness alongside that of participants’ on the 
consent form, handed over the participant sheet while obtaining informed consent and explained to participants that they were in a research study138.  In another, only a third of 
medical professionals reported taking consent in the format advocated in national guidelines135 and far fewer (~ 12%) provided a written copy of the written consent to 
patients.135 There was no research on what information recruiters usually discuss in an informed consent interaction or what patients expect to be informed about. 
o Coercion: In one study that explored if medical students felt coerced into research participation, a quarter of participants stated they had participated in research study/studies 
due to faculty requests, a few did not know they could refuse participation, a third disagreed that participation was entirely their own choice and two-thirds said they had 
participated despite not wanting to. Majority also felt that faculty would like it if they participated and that it will help their academic grades. Overall, authors concluded that 
medical students felt under pressure to participate in research studies and were concerned about the repercussions of refusal.126  
o Experiences of informed consent process (lay participants): Some clinical trial participants in a qualitative study stated that they were not given detailed (or sometimes any) 
information about the trial before enrolment and that the benefits of the drug being tested were sometimes emphasised and presented as the best option available. Many said 
they had signed the consent form without understanding the contents as they trusted their doctor. All participants appeared to be aware of their right to withdraw, but their 
accounts indicated that their decision making for participation may not have been truly autonomous and voluntary (mediated by factors such as gender norms).103 
A.4. Knowledge, attitudes/perceptions and practices in relation to Ethics Committees (including composition, functioning, performance, capacity, review process): Professional (and some 
lay) participants 
Number of studies tagged to topic: 1867,68,73,76,81,89,92,97,98,101,102,108,121,127,130,133,135,137 
Methodological aspects and limitations: 
• Of the seven questionnaire surveys, three used descriptive statistics (n=25, 73, 29)76,89,102 and four used inferential (n= 52, 180,385, 30),68,97,108,130 of which one was reported entirely 
descriptively.108 
• Some information was usually provided on questionnaire administration, with information being limited97,102,130 or unclear/not provided68,76,108 on validation/piloting; and unclear/not 
provided on source(s) used to inform questionnaire development.76,97,108,130 
• Demographic information was not always provided on education76,130, gender76,89,97,108,130 and age76,97,102,130 of participants.  
• Information was sometimes not provided on clinical trial/research training76,89 and clinical trial/research experience.76,97,102,130 
• Three qualitative research studies employed interviews (n=6, 17, 14).73,92,121 
• (Note: Methodological aspects of seven studies included in the synthesis here are within the previous section, A367,81,98,101,133,135,137 Also, findings from one study with lay participants 
that briefly explored views on ethics committees is included here127). 
Synthesised findings: 
• Questionnaire surveys were conducted with dental professionals (dental faculty only81,98 or with dental students and faculty137); medical professionals (medical students and faculty135 
or medical faculty only97); ethics committee members,68,76,102,130 and clinical research professionals (comprising investigators from contract research organisations/public hospitals 
with/without ethics committee members and sponsors).67,89,108,133 Four qualitative studies were with ethics committee members73,92,101,121 and one was with the general public.127 
• Knowledge: Ethics committee composition and functioning: Self-reported awareness (i.e. where participants where asked if they were familiar/aware of a particular topic or not) of the 
functions of ethics committees amongst dental professionals81,137 and self-reported awareness of the composition of ethics committees amongst medical professionals135 were both 
reported to be limited.  Majority (56%) of medical faculty in one study were reported to have below-average to average actual knowledge (i.e. when reported as tested/assessed) on 
ethics committee composition and functioning (explored quorum requirements, member composition, lay representation, frequency of meetings, submission deadlines).97 In another 
study, ethics committee members were reported to be aware of the requirement of a quorum to conduct a meeting, but not how many members constituted a quorum.102 Some 
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studies asked whether participants knew of the presence of any ethics committees and reported that the majority did.81,135 Lay participants in a qualitative study were reported as 
unaware of the role of ethics committees in protecting the interests of research participants or in addressing the violations of their rights.127 
• Attitudes:  
o Ethics committee functioning: There was widespread support for the existence and need for ethics committees among dental professionals,81,98,137 but limited satisfaction 
amongst medical professionals and clinical research professionals regarding ethics committee functioning in some studies108,135 and high levels of satisfaction in others (with 
clinical research professionals).67 About half the clinical research professionals scored ethics committees 5 or over (on a scale of 1 to 10) in relation to their independence133.  
Conflict of interest was considered a key reason for committees’ lack of independence133 and as a barrier to committees’ functioning by investigators.108 Pressures from senior 
management was also considered a reason for committees’ lack of independence by clinical research professionals in one study,133 but only few felt that pressure from sponsors 
was a barrier faced by ethics committees in another study108.  Majority of ethics committee members felt that the committees’ functions should include mediating between the 
media and researchers, monitoring serious adverse events, ensuring the community benefits from the research,68 protecting patient confidentiality and imparting research ethics 
education to investigators.101 Most clinical research professionals believed that auditing ethics committee performance by third parties and the registration of ethics committees 
will improve the functioning of ethics committees and ethical standards.108  
o Regulatory changes: Ethics committee members discussed the evolution of stricter guidelines for how ethics committees function and felt that the ‘bar has risen’ over time.121 In 
another study with ethics committee members from 25 committees, members were in support of regulatory changes (of August 2016, where ethics committees have to take 
responsibility for decisions such as the number of trials per investigator), but felt that the changes were too many, too often and a burden to committees.76 While most ethics 
committee members stated feeling empowered to take a decision on approving the number of studies per investigator,76 fewer investigators were in favour of restrictions on trial 
numbers allowed per investigator.89 Ethics committee members felt that there was lack of clarity on the role of independent ethics committees.76 Accreditation/registration: Most 
ethics committee members were in favour of accreditation for all committees, but identified challenges they encountered with the process for renewal of registration of ethics 
committees (such as lack of clarity with requirements and cumbersome documentation, lack of institutional support and resource constraints and lack of acknowledgement after 
submission of documents). 76 
o Ethics committee composition: Most ethics committee members felt that the committees should be reconstituted every two years and that those invited as members should be 
experts in their field and trained in ethics.68  
o Ethics review: In general, majority of dental professionals supported the need for ethical review for all human research,81,98,137 except surveys and retrospective studies (this was 
amongst dental and medical professionals).98,135 In the same vein of support for ethical reviews, majority of dental professionals disagreed that ethics approval was not necessary 
due to the presence of scientific committees81,98, ethics approval delays research and makes it harder for researchers81,98,137 and ethics review should be restricted to international 
collaborative research.81,98,137 Two-thirds of ethics committee members (of 25 committees) believed that the scientific review committees and the ethics committees should be 
kept separate.76 Most, but not all, ethics committee members disagreed with trials starting before ethical approval to save time.102 More than half the clinical research 
professionals did not feel that the safety review by ethics committees was adequate.133 Most clinical research professionals felt the ethics review process benefits research, but 
also that ethics committees failed to understand research protocols/methodology and sometimes over or under estimated risks of clinical trials.108 The notion of ‘ethics 
committee shopping’ was discussed by committee members, where investigators/sponsors went elsewhere if refused approval at the first.121  There was overwhelming support 
for a single national research ethics committee to consider multicentric trials amongst clinical research professionals,89,108 which is likely to help prevent ‘ethics committee 
shopping’, but there was less support for this amongst ethics committee members.76 
o Research ethics/GCP training: Majority of ethics committee members68,92 and clinical research professionals133 were in support of research ethics/GCP training for ethics 
committee members (although fewer, i.e. ~ 40%, ethics committee members were in support of this in another study102). Clinical research professionals also supported wider 
training for ethics committee members, for example, in regulations and roles/responsibilities of each member.108 Some ethics committee members stated that training was 
challenging to organise for doctors who were busy and that doctors may not require intensive ethics training as they were already sensitised to patient issues and aware of the 
role of ethics in clinical research.92   
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o Ongoing monitoring and on-site visits: Ethics committee members from 11 committees in one study were in support of ongoing monitoring of trials by ethics committees,102 while 
in another study members from five committees were not in support of this and believed monitoring should be the responsibility of third parties or sponsors/investigators.92 Most 
clinical research professionals believed that improving the review process through on-site visits will contribute towards improving the functioning of ethics committees.108  
o Guidelines/regulations: One qualitative research study suggested that ethics committee members intense focus on informed consent, guidelines, legality and regulations in their 
accounts may be because this was a way for committees to gain credibility amongst researchers; strict proceduralism was felt to overtake protection of participants’ interests and 
being humanistic.121 Another qualitative study provided an example where institutional bias was observed (the use of a placebo in a trial was discussed in relation to protecting 
the institute’s interests rather than as a moral dilemma) and that participant protection was often the by-product of the need to safeguard an institution’s legal accountability.92  
• Practice:  
o Ethics committee functioning and composition: Members from eleven ethics committees reported that they function independently and with appropriate representation of 
people with different qualifications as stipulated by national guidelines.102 Most ethics committee members scored themselves above 5 (one a scale of 1 to 10) in relation to their 
involvement in meetings and those from non-medical backgrounds mostly stated that they did not feel restricted by their background while participating in meetings.130 Most 
ethics committee members (from five committees) noted that there was an arbitrariness in member selection, with no policies on selection and reliance on informal networks, 
especially for members not affiliated to the institutions in which the committee is based.  Members affiliated to the institutions, on the other hand, appeared to have limited 
choice in refusing membership in a committee92. Two ethics committees scored 62% and 67% on a quality assurance self-assessment tool for ethics committees.73  
o Ongoing monitoring and on-site visits:  Nearly all ethics committee members from 11 committees said they undertook periodic ethics reviews of ongoing trials, but far fewer said 
on-site monitoring was conducted.102 In another study members from five ethics committees said they did not undertake monitoring of ongoing trials.92 Nearly two-thirds of 
committee members (of 25 committees) said they did not have a well-devised plan to visit sites for monitoring during study conduct and just over a third stated that their 
committees had visited sites for monitoring ongoing studies.76 Ethics committee members from two committees in another study said they required annual and end of study 
reports from investigators.73  Members from 11 committees in a qualitative study highlighted variations in practice.101  Some (contrary to national guidelines) did not see 
committees having a role in ongoing monitoring of research conduct and management of information and explained that their role was over once approval was granted. Others 
stated they intermittently investigated whether studies were carried out appropriately.101  
o Workload and working patterns: The increasing workload of ethics committees was frequently discussed across studies, including that limiting the total number of trials handled 
by committees will improve its functioning.108 Some reported the frequency of meetings across ethics committees (once/week to once/two months102 or 25-70 per year73), the 
number of protocols reviewed per meeting (1 to 20 per meeting;102 50 protocols once/month in ethics committees of public hospitals versus 2-6 protocols once/month in those of 
private hospitals)92 or the number of meetings attended per year by members (1 to 10 per year).130 Some public hospital committees appeared to combine the scientific and 
ethical review at their meetings and were reported as having lesser administrative support than those in private hospitals.92 Most members from 11 committees stated that they 
received proposals two weeks in advance of the review meeting, results were communicated to investigators within a week and that all documents were archived for five years.102  
o Ethical review: One study raised in detail the dilemmas faced by ethics committees in India (as well as Sri Lanka and Nepal) in relation to the growth of pharma industry 
(pharmaceuticalisation) and the ethical review process. Committees face increasing the pressure to assimilate within the international standards of ethical review, while also 
being cognisant of their larger responsibilities towards protecting not just research participants but also national interests121 (for instance, in ensuring research does not reinforce 
existing health and social inequities). 
o Honorarium: Most ethics committee members (from 11 committees) said they received an honorarium for their time.102   
o Documents reviewed: Amongst two ethics committees studied, both were reported as having a policy for how protocols were reviewed, when members received the protocol and 
supporting materials for review, but only one had a checklist for documenting their ethical assessment.73   
o Aspects reviewed: Some committee members outlined the privacy/confidentiality73,101 and informed consent73 aspects that were considered by investigators and reviewed by 
ethics committees (i.e. how data collected was protected, whether lock and key or electronic; process/setting of obtaining informed consent; reading level of informed consent 
forms; and whether they covered the basic elements of informed consent).73,101  
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o Guidelines followed: There appeared to be variations in how and which ethical guidelines were followed by ethics committees.101 All ethics committee members (from 11 
committees) stated they followed national guidelines (ICMR), but fewer mentioned international guidelines (e.g. ICH-GCP, WHO GCP).102  
o Training: Ethics committee members recognised that they had high training needs and majority of members (from 25 committees) said that their committee has a training plan 
and members are trained when there are new regulations.76 
 
A. Primary research: Perceptions, experiences, practices/processes 
A.5. Informed consent processes: Lay (and some professional) participants  
Number of studies tagged to topic: 1370,72,79,83,111,140 including findings from seven studies76,78,89,103,109,127,133 where the focus was not on informed consent 
Methodological aspects and limitations: 
• One large (n=4382)111 quantitative study was based on observations of informed consent discussions and the other was a questionnaire survey (n=150)72, with both employing 
inferential statistics. 
• Of the three qualitative studies, one employed interviews (n=8) and observations of consent interactions (n=5)79, another involved audio-recordings of consultation recordings (n=100)83 
and the third was a case study of a contract research organisation (CRO) conducting bioavailability/bioequivalent (BA/BE) studies, comprising interviews with CRO staff (n=8), group 
discussion with healthy volunteers (n=50) and observations of informed consent discussions (n=40).140 
• A mixed methods study involved a questionnaire survey (n=332; descriptive) and one focus group discussion.70 
• Methodological aspects of the additional seven studies76,78,89,103,109,127,133 are in other sections. 
Synthesised findings: 
• Studies were mainly conducted with lay participants (general public,72 healthy volunteers in BA/BE studies,140 potential clinical trial participants,70,79 including parents of children83,111). 
Three studies also included views of researchers70,79 and CRO staff.140 
• Only one study described the process of customising the informed consent process to the trial population. The informed consent procedure for an RCT with people with schizophrenia 
was developed with prior feedback from participants/caregivers, incorporated the feedback received (such as simplifying the information sheets, developing a flip chart with diagrams 
to explain key study elements, making the consent procedure more interactive) and then evaluated the feasibility of this informed consent process from multiple perspectives. The 
informed consent process and the use of the flip chart were found to be useful by participants and study personnel. Study personnel found the manual-based training and ongoing 
support to be helpful and noted that concepts such as trial, research and randomisation were difficult to convey and required considerable time to explain.70 
• Patient participation in informed consent discussions: The questions asked by parents/guardians of potential child (infant) participants during discussions varied from 13% in a study 
where the discussions where preceded by a community information session (study physicians/research nurses were not involved in consent process; study personnel trained on ICH-
GCP guidelines were instructed to encourage questions from participants and note down questions/comments at the back of the consent form when questions went beyond simple 
clarifications of informed consent form; study was conducted by an organisation that has provided charitable health services in the community for more than 30 years)111 to 55% in 
audio-recordings of consultations.83 Most frequent questions asked include who to contact in an emergency, risks to child, questions specific to the condition being studied (such as 
tuberculosis) and benefits to child/family of participants.83,111 Education,83,111 higher socio-economic status, and the presence of both parents were associated with asking questions.111 
Some participants in a qualitative study (interviews exploring hypothetical trial participation), especially those who were less educated and did not know the meaning of research, 
stated that they would not ask the doctor any questions about the trial, despite lacking sufficient information.127 In a qualitative study of healthy volunteers for BA/BE studies, 
observations of informed consent discussions revealed that the volunteers’ concerns revolved mainly around the payment they would receive for participation than about their own 
health.140 
• Recruitment process/experience and informed consent process: A qualitative study that examined a CRO as a case study found that healthy volunteers were recruited for 
bioavailability/bioequivalent studies through lists created through networks and middlemen who are paid a commission for recruitment. These volunteers constituted a pool of readily-
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available participants regularly approached for participation, with many volunteers exceeding the maximum number of studies they are allowed to participate in per year. CRO staff 
stated that some CROs have systems in place to thwart such irregularities, but others did not, facilitating serial participation. CRO staff also noted that most volunteers had decided to 
participate much before they attended the informed consent discussion or saw the consent documents, with the subsequent informed consent process being a mere formality. Contrary 
to accounts of family-based models of informed consent being the norm, volunteers were unaccompanied during discussions and nearly all (48/50) said they decided to participate in 
the bioavailability/bioequivalent studies without informing their families as they would not allow the volunteers to participate and would see the volunteers as selling their bodies for 
money.140  
• Audio-visual (AV) recording of informed consent discussions:  
o Acceptance: In a study that used a hypothetical scenario to assess acceptability, a third of the (lay) participants refused consent for AV recording of consent,72 whereas nearly all 
(lay) participants who expressed an initial willingness to participate in a real vaccine trial agreed to undergo AV consenting process.83 In a study where AV recording process was 
observed, it was noted that patients and investigators were uncomfortable (self-conscious) due to the process,79 whereas authors in another study noted that while patients 
seemed intimidated by the AV consent process at the beginning, they became more relaxed and comfortable after it was explained and they started to participate in it.83  
o AV process: Consent discussions that were audio-recorded were described as being undertaken in private spaces79,83, without any other individuals present79 or with an impartial 
witness if the patient was illiterate,83 after separate consent for AV recording,79,83 with recordings stored with password protection.79 Time taken for the AV process varied from 
30-45 minutes83 to an hour-and-a-half to two hours.79  
o Perceptions of AV recording: Support for the AV recording process among professionals varied (nearly two-thirds of clinical research professionals,133 just over a third of 
investigators89 and investigators in general in a qualitative study79 were reported to be in favour of the AV recording of informed consent). Investigators expressed concerns about 
the lack of guidance and training to support them79 and investigators and patients were concerned about the extra time that was required to undertake the AV consent 
process.79,89  Key informants (investigators, from sponsor/contract research organisations, ethics committee members) and patients had privacy and confidentiality concerns with 
the process.79,89,103 Other concerns included that it may cause anxiety and discomfort amongst participants and that it would affect large-scale community studies.89 Some authors 
reported that they did not have the commonly reported problems of lack of infrastructure or any issues around sound quality, training of personnel and storage/retrieval of 
recordings.83 More than three-quarters of ethics committee members from 25 ethics committees felt that the informed consent process was adequate in their institutions, but 
less than half stated that their ethics committees review AV recordings if there were reports of noncompliance/protocol deviations in the informed consent process.76  
o Role in improving informed consent: Only few investigators believed that the AV recording of consent process would improve informed consent in one study.109 However, there 
was a notion amongst some investigators (and study authors) that the AV recording of informed consent process increases investigator responsibility, accountability and 
transparency of the process, and that it provides legal protection to participants.83,89 An observational study that compared informed consent comprehension scores amongst 
participants before and after the introduction of the mandatory AV recording for the consent process found better comprehension after78 (the duration between consent and 
questionnaire administration was shorter in the AV group). 
 
A.6. Bigger picture: Professional (and some lay) participants 
Number of studies tagged to topic: 20 (studies and themes that covered cross-cutting ethical issues are included here) 
• Seven studies (not included in above sections) that explored larger issues were mostly qualitative studies employing interviews or interviews with focus groups (n=66, 42, 83, 25, 25, 43 
participants)84,90,105,114,115,128 and one mixed methods study (n=80 questionnaires, 14 interviews, 119 informed consent documents).125 
• Findings from a further 13 studies67,75,76,90,92,103,108,109,112,127,130,133,140 (methodological aspects included in sections above) that touched upon these larger themes have also been included 
in this section. 
Synthesised findings: 
• The seven key studies included here were primarily conducted with professional groups, such as staff from contract research organisations (CROs),90,115 EC members,84,125,128 (including 
judges, social workers, bureaucrats, medico-legal experts),90 trial sponsors,90,125 investigators/researchers,90,125,128 (including academic public health/medical researchers and health 
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activists from non-governmental/civil society organisations)114 and employees or participants in research conducted by non-governmental/community organisations.84 One study 
included participants from both professional (key informants such as representatives from civil society organisations, community leaders, advocates, services providers, trialists) and lay 
groups (community members, former trial participants and individuals from HIV high-risk groups).105 Similarly, of the further 13 studies that have been drawn from, all except two103,127 
were with professional groups and one was with professional and lay participants.140 
• Compensation (n=10): 
o Free medicines/vaccines/treatment and post-trial drug access: A qualitative study reported that lay participants who were educated and from high socio-economic groups felt that 
the product (vaccine) should be free to motivate participation as it is still being researched and not on sale.  However, ‘free’ meant inferior or dangerous, especially to some from 
lower socio-economic groups, who compared it to government hospitals being free and providing poor services.127 There was mixed support for post-trial drug access amongst 
doctors,75 investigators67 and clinical research professionals133 with many but not all supporting it (in two of these studies, majority of respondents were from industry/private 
sector and the study authors were from a pharmaceutical company67 and a contract research organisation133).  
o Payment for participation: Amongst lay participants with a poorer understanding of research and a higher therapeutic misconception, payment for participation was not 
acceptable. Some were also sceptical that being paid would mean the sponsor would have lesser responsibility towards them, thereby making the participant more vulnerable. 
Others felt it was their right or their due, a way of showing appreciation for taking part, an important way to compensate for potential risks/inconvenience, an incentive and a way 
to make the participant accountable.127 In another study, investigators supported a reasonable daily/travel allowance for the study visits and emphasised the need to reassure 
patients that they would not have to pay from their own pockets.67 In a qualitative study, healthy volunteers were observed bargaining for incentives that were much higher than 
what was in the protocol and approved by ethics committees.140 
o Payment for researchers: Amongst lay participants whose motivation for research participation was altruism, there was little support for payment for doctors/researchers to 
conduct research as they felt that doctors/researchers should also have the same attitude, especially if they were already being paid for their jobs and where the patients’ 
participation was voluntary.  Payments for doctors/researchers was felt to be particularly unethical if they were paid per patient recruited.  Others felt it was fair for 
doctors/researchers to be paid for their research work but that this should be reasonable, and were in support of transparency and disclosures regarding payments for 
doctors/researchers.127 
o Compensation for study-related injuries/serious adverse events: Most clinical research professionals (sponsors, investigators, ethics committee members) were aware of the 
Indian laws and guidelines regarding compensation for clinical trial related injuries, but far fewer said they were compliant with them or implemented them.125 On the other hand, 
a qualitative study with a similar participant profile reported that key informants (sponsors, investigators, ethics committee members, contract research organisation 
representatives, programme managers) lacked clarity on the provision of insurance and compensation for trial related injuries and trial participants were completely unaware of 
compensation arrangement or insurance provisions for trial-related injuries103 (note: both studies were conducted prior to the introduction of new regulations on compensation 
in 2013). Most (not all) clinical research professionals (investigators, ethics committee members, sponsors) were in favour of compensation for trial-related injuries/serious 
adverse events, the new regulations on them and felt able to navigate the stipulated processes, calculations and timelines in relation to these.76,89,103,133 One study reported that 
while most clinical research professionals supported compensation for travel, fewer were in support of payments for participants’ time, study risks, inconvenience caused by 
participation or as an incentive for participation.109 Ethics committee members stated that they did not have the time or the expertise to review compensation plans for trials, 
although they felt it was important. Also, most were reported as not being aware of the details of insurance contracts, although their review and approval was part of committee 
members’ responsibilities.125 Some ethics committee members felt that compensation determination should be outside the remit of institutional ethics committees, that defining 
risk in the compensation formula was challenging and were in support of training for members on the topic.76 Studies conducted before the new regulations reported that the PI, 
sponsor and EC members were involved in deciding the level of compensation based on various factors (such as number of dependents, age, type/stage of disease, etc)103 and 
that compensation appeared to be limited to acute management of adverse events during the trial (which the patient has to pay for and would be compensated later); clinical 
research professionals did not mention compensation for lost wages during the adverse event/death and permanent disability, even thought it is mentioned in the national 
guidelines.125  
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o Adverse event reporting: A qualitative study reported that key informants lacked clarity on the timelines and process for reporting adverse events. The study reported that in 
practice it appeared that trial participants were given a list of possible adverse events and numbers to contact if they occurred, but some participants did not report these and 
sought help from local doctors, which meant they were not reimbursed for their expenses. The authors noted that most adverse events were not recorded as linked to clinical 
trials and that it appeared that most were recorded primarily for reporting purposes (e.g. to sponsor).103 
 
• Sharing of data, blood/tissue samples, results and benefits (n=3): In general, findings acknowledged that there appeared to be limited experience of data sharing and it was perceived as 
a new territory, amplifying participants’ reservations.84  
o Blood/tissue samples sharing: Lay participants in a qualitative study on clinical trials and biobanking research initially readily agreed to have their blood/tissue samples stored for 
future research/sharing (as it was ‘outside the body’ anyway, was a ‘waste’ for the individual, etc), but were more discerning when probed and given further information.127 
Participants were generally positive about samples being used for future genetic research, but concerns were expressed regarding misuse of samples, ethical issues, commercial 
exploitations, manipulation of nature and eugenics.127 
o Medical records/clinical data sharing: This was perceived as non-controversial by lay participants as long as they were used for beneficial purposes and confidentiality was 
maintained; some however preferred being informed about the reason the records were needed (participants were unaware of legal position on sharing of personal data). While 
some participants felt that anonymising data would make the sharing of illness/medical history acceptable, others preferred restricted disclosure only to those concerned with 
research, mainly due to concerns regarding security of electronic information and the stigma around certain health conditions (despite this, participants appeared to prefer being 
contactable in the case of genetic research, where there was a possibility of individual findings being shared).127 
o What is data?: The meaning of ‘data’ was explored in a qualitative study with researchers, managers and research participants (mixed population group comprising professional 
and lay participants) associated with non-governmental organisations.84 Data was perceived as including but not limited to demographic/household details, images, videos, 
medical records and both qualitative and quantitative information. All data was perceived as possibly sensitive as it may have the potential to harm an 
individual/community/organisation (e.g. HIV status, sexual behaviour), but this mixed population group felt that data could be shared if anonymity could be guaranteed.84  
o Benefits/harms of data sharing: Benefits of data sharing discussed in the mixed population group included evidence generation, increasing transparency/validity of findings, 
avoids duplication of efforts and burdening participants with similar research and encouraging learning. Harms of data sharing were mainly the misuse of data, primarily for 
commercial activities and market research, and the potential for harm to patients/communities, even if data were anonymised, especially when the aims of the data accessor was 
not clear. It was also felt that participants may refuse to participate in a study or provide incorrect information if they were aware that data may be shared with third parties that 
they do not know of.84 
o Barriers to data sharing: Lack of experience, competitive working environments, scepticism of the motives of data accessors and the work required to clean and share data, 
especially qualitative data were all discussed as barriers to data sharing amongst lay and professional participants.84 Lay participants indicated that not knowing the 
individual/institution that would access their data later made it difficult to trust them.127 
o What could help? Some participants (lay and professional) felt that data sharing would be acceptable when it was with reputed institutions, where it was managed rather than 
open access to data and with governance/policies in place, including on sharing, authorship, payments, ownership and protection of data from misuse.84 Lay and professional 
participants also felt that data sharing was justified if it directly led to interventions or solutions to health issues rather than when it was simply used to write articles (some 
argued that it would be okay to share data even without direct community benefit if it meant others would learn from it).84 
o Confidentiality: There was agreement that this was key,128 with the responsibility for this laying more with the data sharer (i.e. initial researcher) than with the data accessor (i.e. 
who later requests for access), as the participant trusted the researcher they initially provided consent to.84  However, this was acknowledged as particularly difficult for 
qualitative research. 
o Payment for samples: Ethics committee members and medical researchers in a qualitative study discussed the ethical dilemmas around paying participants for samples.128 While 
making profits out of someone’s sample while excluding them from the benefits was not deemed acceptable, being paid was seen as equivalent to tissue trafficking and tissue 
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being seen as a commercial commodity. Some felt that paying participants could lead to unethical practices, while others felt that it was not acceptable to expect one-sided 
altruism from participants. They argued that payment for contribution is fair as participants have a right to monetary benefit, especially when the samples led to commercial 
development and benefit (as opposed to academic research).128 
o Benefit sharing: Lay participants spoke of a community development approach (which involves giving back to the community/medical field, for e.g. through low-cost healthcare) 
and a participant focussed approach (as the individual agreed to take part when there was uncertainty around the drug) to sharing the commercial profits that were gained by 
pharma companies after a successful research study.127 Similar views were expressed by ethics committee members and medical researchers (giving back to the community by 
supporting further research or healthcare provision in the area, especially when outcomes of studies are commercialised for profits).128 Giving back to the community as opposed 
to directly to the individual was also seen as a way of protecting individual confidentiality.128 
o Sample ownership: In the context of biobanking research, sample ownership was seen as a grey area by ethics committee members and medical researchers. It was seen as the 
patients’ (as the needs/interests of the sample contributor were of utmost importance), custodians’ (where the storage facility/department/laboratory was the technical owner 
with responsibility for safe-keeping and prevention of misuse), and the researchers’ (as the consent form transfers the ownership from the sample contributor to the researcher). 
There was also some limited discussion of the difference between ownership of samples/clinical data as opposed to  ownership of research data, with former belonging to the 
patient and latter to the researcher.128 
o Disclosing individual findings: This had not been given much thought of by most ethics committee members and medical researchers, but generally respondents felt that 
actionable individual results that have clinical significance should be made available to the sample contributor. These views were recognised as being different to countries like 
the United Kingdom (where individual results were not shared with the contributor), but given the lack of universal health coverage/health insurance and the socio-economic 
context in India, letting the sample contributor know their results was seen as a way of ‘giving back’.  It was acknowledged that the mechanisms to carry out this out may be 
challenging, with suggestions for who could do this ranging from the treating physician, counsellors, social workers or through a special facility that would liaise between the 
sample contributor and researchers to convey findings and provide counselling (via social workers, not medics).128 The views of participants regarding disclosing individual findings 
following biobanking research varied from being unsure (reasons: consent not taken/discussed beforehand, confidentiality violation/sensitive issues, difficulties with insurance), 
definitely no (reasons: treatment and research are different, findings are irrelevant to patient care, possibility of psychological harm) to definitely yes (reasons: ‘giving back’, 
moral obligation, prevention).128 
o Consent for data sharing: Lay participants discussed the need to give participants the option of blanket/general consent or detailed consent at the time of initial consent.127 While 
discussing three different types of consent options (namely broad consent, where participants would be told that their data may be shared with others in the future and the 
research organisation would decide if sharing is appropriate; middle consent, where participants would be told that data may be shared with people from specific research areas; 
or explicit consent, where participants would be contacted when there was a request for consent), most respondents favoured broad or middle consent. They suggested qualifiers 
such as informed participants about the possible data accessors.84 
 
• Power imbalances (n=17): Unequal power dynamics were explored across different groups and contexts. 
o Doctor-patient relationship and therapeutic misconception: Members of the general public did not appear to be familiar with rules and regulations in relation to biomedical 
research and felt a sense of hopelessness in relation to tackling medical negligence and violations of participant rights due to the differences in power between doctors and 
patients (‘we are small, they are powerful’).127 This power imbalance and a hierarchical paternalistic relationship, along with a doctor’s dual role of caregiver-researcher, influence 
on patient decision making in trial participation and patients’ immense trust in a doctor’s judgement, especially when they provided assurance about a new unproven treatment 
(therapeutic misconception), were reported in qualitative studies.103,127,140 Authors highlighted these as reasons why the informed consent process should be kept away from the 
treating physician.103,127 Therapeutic misconception was also reported as more pronounced amongst those from vulnerable groups (e.g. chronically or terminally ill and from 
lower socio-economic groups), making them more likely to agree to trial participation.127 
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o Population groups recruited to trials, informed consent and exploitation: There was a strong view among representatives from civil society organisations and key informants that 
trial participants were mainly the poor, from rural and tribal communities, who were easy targets as they had limited financial means to access healthcare on their own.103,114 
There was also some suggestion amongst key informants and contract research organisation staff that this was not by chance but a deliberate attempt to recruit from 
economically disadvantaged groups in slums, targeting mostly unemployed people for volunteer studies as well as, sometimes, Phase III trials.103,105,127,140 In a qualitative study 
with healthy volunteers for bioavailability/bioequivalent studies, there appeared to be a unique equation between the volunteers, the middlemen who recruited them and CRO 
staff. While all the volunteers were from lower socio-economic groups and stated that the financial incentives were their key motivation for research participation (seen as an 
alternative career prospect), they were aware of the CRO’s dependence on them and were observed demanding higher incentives to join or not quit the study, often with the help 
of the middlemen who recruited them. Volunteers were observed negotiating a better financial deal for their participation, which was much higher than what was in the protocol 
and approved by ethics committees.140 However, nearly every ethics committee member and investigator in a qualitative study denied that it was the poor, unemployed, working 
class and uneducated who were lured into clinical trial participation due to free treatment or other inducements. Some noted that there was no exploitation as many of their poor 
and illiterate patients were intelligent and asked decisive questions, while others argued that their participants were not rich or poor, but middle class and well aware of their 
rights.90 Some staff from contract research organisations insisted that trials that involved such organisations followed the highest standards and that there was no ethical 
variability in informed consent processes for trials conducted in India as opposed to the West, as any lack of rigour and diligence would not be acceptable to Western 
sponsors.90,115 Representatives from civil society organisations, on the other hand, felt that there was ethical variability between trials in the West and in India, framed within the 
context of fewer ethical guidelines and regulations in India. They also stated that informed consent was majorly compromised and ‘meaningless’ when the majority cannot access 
treatment unless they participated in a trial due the failed public health system.114 Many investigators (mainly recruited from the private sector) agreed that participants agreed 
to take part in trials to have better access to physicians and/or medical care.67  
o West-East, North-South, developed-developing divide: Frontline health service providers, including some doctors in a qualitative study were reported as feeling that certain types 
of research (such as HIV vaccines) were concentrated in third world countries as they would not be acceptable in the West.112 Most clinical research professionals believed that 
clinical research between developed and developing countries was inequal.109 Ethics committee members and representatives from civil society organisations viewed Western 
pharmaceutical trials that recruited from India as a manifestation of the continuing post or neo-colonialist relationship between Western countries and India.114,121  
o Are clinical trials relevant to the needs of India?: Most investigators (from the private sector in a study conducted by authors employed by a pharmaceutical company), felt that 
studies were relevant to the needs of India and most also believed that the active comparators used in clinical trials in India were usually the same as in the developing world. 
However, the majority also agreed that pharma companies should set common research goals for all communities and countries.67 By contrast, ethics committee members 
believed that pharma companies were using India as a dumping ground to study drugs that are not required for the country’s population.92  Similarly, some investigators in a 
qualitative study strongly felt that there was a lack of correlation between the disease burden in India and the type of clinical trials that are conducted in the country. Some of 
them in leadership roles lamented the lack of requests to conduct trials for tropical diseases (although many suffer or die of them) and the large number of trials for conditions 
that mirror the disease profile in the West (such as diabetes, heart problems, cancer), which is similar to urban India. They therefore felt that trials conducted in India cater to a 
small segment of the local population and do not benefit the majority of the population, which is poor.90 This narrative ran counter to the views of executives from contract 
research organisations who saw clinical trials as benefitting society and their participation in them being about advancing science rather than the pursuit of financial benefits.90 
Some ethics committee members also opined that foreign sponsors should not be expected to take up responsibility for public health in India when the state had itself failed in 
their social responsibility of delivering healthcare to the majority of the population.92  
o Capacity building: In a qualitative study with employees of contract research organisations, authors noted that in most trials that they studied, the role of these organisations was 
focused on downstream activities, merely executing the protocols and agendas set by international pharmaceutical companies, following procedures to do the trials ‘right’ and 
meticulous documentation (all as part of the phenomenon described by the authors as big-pharmaceuticalisation), with little evidence of locally relevant innovation and 
knowledge production. However, despite carrying out tasks central to clinical trials, as these organisations delivered a paid service, they had no intellectual property rights and 
their names did not feature in trial databases or in publications.115 Representatives of civil society organisations similarly expressed concerns that Indian researchers and 
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organisations (terms such as ‘servants’ ‘coolies’ and ‘implementing agency’ were used) merely provided labour to produce global data (terms such as ‘pre-cooked research’ and 
‘pre-defined research questions’ were used) that benefitted the global North and reinforced existing global hierarchies rather than leading on innovation relevant to the local 
population. Some noted that the Indian researchers doing the research rarely attain leadership roles and when they do, it appears to take a much longer time to break the glass 
ceiling.114  
o Community engagement in research: Community advocates reported feeling like they were simply being ‘used’ by research teams to recruit participants to studies without true 
engagement in all aspects of research. There was also a general mistrust of authorities/researchers conducting or involved in clinical trials, with some questioning why trials 
needed to be conducted in their countries.105 
o Lay participation in ethics committees: Two-thirds of ethics committee members with a medical background were in favour of including lay people or patients in committee 
meetings, while only a quarter of members with non-medical backgrounds were in favour of this. Majority of those with non-medical backgrounds stated that their lack of a 
medical background did not make them feel restricted from participating during committee meetings.130 However, two-thirds of clinical research professionals felt that lay people 
were unable to contribute adequately in ethics committee meetings.133 Similarly, non-medical, non-scientist members of ethics committees in a public hospital expressed 
difficulties in participating in committee meetings without adequate training and reported feeling like ‘show pieces’ with an obligatory presence. Medics and scientist members 
were reported as being the assertive voices due to the hierarchy between medical and non-medical experts and the technical nature of trial protocols.  Additionally, some 
members mentioned that protocols prepared for the technical (or scientific) committees were presented to ethics committees without any adaption or highlighting of ethical 
issues.92 Other key reasons mentioned by clinical research professionals for difficulties faced by lay members of ethics committees were lack of training in GCP, regulations and 
ethical thinking, inadequate exposure/training in clinical research, human rights and compensation, power imbalances (voice can be easily overturned by experts), being unaware 
of the importance of their role and being used to merely meet quorum requirements.108,133 Some non-medical experts (social scientists) noted that not being connected to the 
institution where the research is to be conducted has its advantages as it is easier for non-affiliated members to raise questions than their clinical colleagues who may fear 
offending their colleagues/institution, but that they have little power to change things.92 
 
• Contract research organisations (CROs), civil society organisations (CSOs) and the clinical trial industry (n=7):  
o Tracing the growth of CROs in India: One qualitative study that explored the views of CRO staff in relation to a range of ethical issues in clinical trials, outlined the growth of CROs 
in India.115 Participants outlined how the pharmaceutical industry, in the pre-TRIPS period, aimed for self-sufficiency as drugs were required in large numbers and clinical trials 
were not a priority as the focus was on making generics. However, participants observed that more recently, there has been a move towards biosimilars, which involves producing 
drugs that are similar to, but slightly different or more advanced than, existing drugs. This move from generic drug manufacturing towards innovative research by local pharma 
companies (which the authors call ‘big-pharmaceuticalisation’) was seen as a stepping stone towards the development of new chemical entities (although this was perceived as 
unaffordable to Indian pharmaceutical companies as the industry was not big enough to afford the millions that developing new entities costs). The authors noted that these 
accounts of progress were embedded within narratives centred on CRO operations/motives and participant safety, with limited mention of the larger ethical issues such as post-
trial benefits for participants, compensation or whether the drugs developed provided therapeutic advantages over existing drugs. There was a feeling that the regulatory 
landscape in India was slow and did not keep up with the fast-paced growth of clinical trials.115 
o CRO operations and collaborative models: The same qualitative study outlined participants’ accounts of the processes by which international pharma companies contact Indian 
CROs or international CROs with offices in India to conduct trials. CROs advertise their services on various platforms, including online and in conferences, and approach doctors at 
private and public hospitals and from those listed on the clinical trials registry of India to act as investigators. Participants also discussed six collaborative models between CROs 
and sponsors and three different types of trials conducted by CROs.115 Another qualitative study outlined the process through which middlemen were engaged by CROs to recruit 
healthy volunteers for bioavailability/bioequivalent studies, creating a pool for participants who were regularly approached for participation (serial participation) and often paid 
more than agreed in protocol/approved by ethics committees in order to retain their ongoing participation.140 
BMJ Publishing Group Limited (BMJ) disclaims all liability and responsibility arising from any reliance
Supplemental material placed on this supplemental material which has been supplied by the author(s) BMJ Global Health
 doi: 10.1136/bmjgh-2020-004729:e004729. 6 2021;BMJ Global Health, et al. Paramasivan S
15 
 
o Malpractice and scandals: Most CRO staff were critical of the instances of corruption and malpractices amongst CROs reported in the media, but mainly spoke of these as 
malpractices by ‘others’ and never themselves – a narrative that the authors found to be vulnerable as at least one CRO in the study was implicated in a widely reported clinical 
trial controversy in Bhopal115 (with evidence of malpractice reported in another study on CROs140). Also, while participants were not critical of the new regulations introduced in 
2013 following the spate of controversies, they were critical of the lack of government support and protection in the wake of media attacks.115 
o Motivations of those involved in clinical trials: Most CRO executives and investigators stated they were not involved in clinical trials for monetary gains but as a service to science, 
humanity and society, considering that it involved risks and expressed their unhappiness over the media portrayal of the industry.90 Some activists expressed concerns about 
ethics committees becoming financially focussed and providing easy approvals to benefit pharma companies.114 
o Views on pharma-sponsored clinical trials: Nearly two-thirds of doctors believed that trials done for academic purposes, including for dissertation purposes, were relatively more 
ethical and scientific than industry-sponsored trials and that regulations/legislations related to industry-sponsored trials are inadequate. More than half opined that patients are 
exploited in industry-sponsored clinical trials.75 Ethics committee members in a qualitative study were concerned about the role of pharma companies in manipulating clinical trial 
agreements between the sponsor, investigator and institution, to suit their own interests.92 By contrast, favourable views regarding pharma-sponsored trials were expressed by 
investigators (mainly from private sector) in a study authored by researchers in a pharma company.  They felt that pharma trials addressed the needs of the community, but 
agreed that the drugs that were developed were eventually unaffordable to majority of the local population.67 Representatives from civil society organisations saw commercial, 
industry-driven clinical trials as having a corrupting effect on many fronts – it lured good investigators away from academic research with the promise of financial benefits and 
contributed towards good research questions being side-lined if they did not have commercial benefits.114 
o India as the preferred destination of choice for clinical trials: CRO executives and investigators felt that India was preferred not just because it was cost-effective to conduct trials 
in the country and there was a larger proportion of treatment naïve population, but also because of the high quality of work that was produced by Indian researchers. Others 
offered more practical reasons such as the need for pharma companies to investigate a drug’s pharmacodynamics within non-White population groups before they could be sold 
to them. Some executives and investigators questioned these narratives and felt that the clinical trial industry was not yet established, that India was not as preferred as was 
originally predicted and that the population was not as treatment naïve as portrayed due to the common use of over-the-counter medications.90 
o Role of CSOs in changing the regulatory landscape in India: A qualitative study traced the role of health social movements in bringing about more stringent regulations (in 2013) to 
protect trial participants.114  Members of CSOs drew from interpretations of social justice and emphasised a rights-based approach to health in their accounts of the activism that 
brought about key regulatory changes. They acknowledged the importance of randomised controlled trials for the advancement of science, but expressed concerns about the 
disregard for the wider ethical issues (beyond procedural and informed consent focused agendas) and the perpetuation of existing global hierarchies through pharma companies’ 
choice of drugs, conditions and populations being studied. They stated that pharma companies and CROs are known for their lack of ethical oversight if left to themselves. Some 
members expressed the challenge in being nuanced or balanced in their debates about clinical trials, while being angry at the injustices in the industry. Some activists spoke about 
the evolution of their views over time from purely ideological to the more pragmatic, to accommodate a need to move away from dichotomous categorisations based on the 
funding source for trials (Indian and public being good versus foreign and private being bad).114 
B. Secondary research   
B.1. Secondary research: Primarily documentary 
Number of studies tagged to topic: 23 
Methodological aspects and limitations: 
• Documents studied included informed consent documents (n=138, 30, 50, 300, 119),64,86,95,107,125 insurance documents (n=18),125 application forms of research projects submitted to 
ethics committees (n=100, 73, 100, 445),85,99,118,120 ethics committee site visit reports (n=7),119 data/records related to research participants (n=42),110 ethics approval letters (n=20),123 
other ethics committee governance/administration related documentation (such as approval letters, meeting minutes, project registers/files) where the time period of data collection 
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was mentioned in place of sample size,66,96 and data from websites of regulatory, accreditation and registration bodies106,139,141 (note: one of the articles included here is also in section 
G).125 
• Reporting practices in journal articles, journal editorial policies and the clinical trial registry in India are also included here.63,71,74,93,94,124 
Synthesised findings: 
• Completeness, errors and quality of data and documentation in research studies (n=6): The most common issues in research application forms submitted to ethics committees were 
missing or inadequate information in relation to study titles, participant profile, study benefits, key signatures (investigators, patients), budget details, recruitment methods, 
compensation for participation or study-related injuries, conflicts of interest, patient safety factors, study documentation, duration of study, sponsoring authority and details on 
informed consent.85,118,120 Some of these were reported as more common in academic studies (mainly dissertation projects and some investigator-initiated studies) than sponsored 
studies (mainly industry sponsored and some government sponsored).120 One study that examined participant data quality and documentation in investigator-initiated and industry-
sponsored studies found that accuracy and data completeness were similar across the two groups, except in documentation related to informed consent processes that were somewhat 
better in industry-sponsored studies.110 A study investigating ethics approval letters for compliance with regulations noted the common issues as lack of information on ethics 
committee members who attended the meeting and their designations, absence of legally required quorum (similar to findings in another study68) and legal experts, social scientists or 
ethicists.  Similar to studies above, the issues that were raised by ethics committees in these letters were often in relation to patient recruitment methods as well as other issues such as 
insurance  policies and clinical trial agreements.123 A study that reported findings from seven site visits119 observed similar issues to those that reviewed research applications forms 
submitted to ethics committees.85,118,120 Authors observed inadequate informed consent documentation (such as missing signatures of patients/PIs and use of forms in local languages 
that had not been approved by the committee) and delays in reporting of serious adverse events.119 
• Impact of regulatory changes on registration/accreditation status and composition/structure of ethics committees (n=2): A study of governance/administration related documents in 
two ethics committees found that the regulatory changes of 2013 had an impact on the structure and functioning of the committees. The number of registered studies reviewed 
remained the same before and after the regulatory changes, but the number of studies approved decreased. However, there was an increase in turnover time. Similarly, the number of 
serious adverse events that were reported increased, but the number of meetings to discuss these events increased and the committees’ income decreased while their expenses 
increased. There was also more administrative workload and documentation after the changes.66 A study that aimed to investigate if the 2013 regulations requiring accreditation and 
registration (and registration renewal every three years) of ethics committees were adhered to, examined information available on national registration and accreditation databases.106 
The study found that most ethics committees registered were institutional with a fifth being independent, but that the registration numbers may not be reflective of the actual number 
of committees in India. Of those eligible for re-registration, more of the institutional ethics committee (nearly two-thirds of eligible) were re-registered than the independent ones (less 
than a third of eligible) and of those that applied for accreditation, less than 10% had received it. The study also found that the distribution of committees across different states was 
skewed (states with similar populations had large variations in committee numbers – for instance Maharashtra and Bihar with similar populations had more than a quarter and less than 
1% of all registered committees respectively). Similar issues arose while comparing registered clinical trials and medical colleges against ethics committees per state, with authors noting 
that this reflected and perpetuated existing health inequalities across states.106 
• Reasons for uninitiated studies (n=1): Another study that similarly studied the governance/administrative documents from the same two ethics committees as above found that a 
greater proportion of pharma-sponsored studies were not initiated after queries raised by ethics committees than investigator-initiated ones. Also, the former had mainly ethical 
queries raised, while the latter had primarily scientific queries raised by the committees. Most of the ethical issues that were not addressed were related to the informed consent 
document or processes. Key scientific clarifications required were on sample size, eligibility criteria and inappropriate study design, while ethical queries raised by the committees were 
in relation to the lack of provision of free investigations or treatments/medicines and patient safety concerns. There appeared to be evidence of ‘ethics shopping’ as some of the 
uninitiated studies in multi-centric studies were found to be registered on the trials registry (CTRI) as ongoing or completed at other sites in the country, and these had mainly received 
ethical queries from the original ethics committees.96 
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• Are clinical trials relevant to the needs of India? (n=2): Two audits of the Clinical Trials Registry of India reported that there was a mismatch between the illnesses researched by clinical 
trials and the country’s disease burden.139,141 Infectious and parasitic diseases rank first in terms of disease burden but 7th in the number of trials registered in that therapeutic area, 
while nnon-communicable diseases such as cancer and diabetes mellitus, which rank 6th and 13th in relation to disease burden rank high up in the number of trials registered (ranks 1 
and 2 respectively).139 
• Compensation (n=6):  
o Compensation for participation: In a study that aimed to investigate the payments allowed for participation in a trial by ethics committees, authors accessed application forms 
submitted to committees as well as other relevant documents (study protocols, informed consent documents and correspondence with investigators). They found that nearly all 
observations studies and a third of interventional studies reviewed by three ethics committees over two years had no mention of compensation for participation. Payments by 
pharma and government sponsored studies were greater than that by investigator-initiated studies. The most common reasons for payment was reimbursement for travel 
purposes. Committees had no particular policies or standard operating procedures in place for practices regarding compensation for participation and the amount of 
compensation approved for participation across studies varied hugely. It also appeared that healthy volunteers were paid more than patients.99 In another similar study, 
statements about compensation for participation were not mentioned  in nearly all academic studies, more than half the government sponsored studies and in about a third of 
industry-sponsored studies.120 
o Compensation for study-related injuries/serious adverse events (including their management): In application forms submitted to two ethics committees over a year, statements 
related to compensation for injury were not mentioned in nearly all academic and government-sponsored studies and in less than a fifth of industry-sponsored studies.120 
Similarly, a study examining application forms submitted to one ethics committee over more than a year found that statements related to compensation provision if risk occurred 
was not mentioned in all applications.85 However, a study investigating informed consent documents submitted to one ethics committee over three years found that information 
relating to compensation for participants for disability/death from research-related injury (Indian GCP-specified) in informed consent documents was improving over time.107 A 
similar observation was made in another study that also examined informed consent documents submitted to three ethics committees over seven years. Authors reported that 
the documents only mentioned compensation for research-related injuries from 2003 (although the guidelines for this existed from 2000), but that the coverage of the issue in 
informed consent documents increased from 2003 to 2007.125 In a similar study examining informed consent documents submitted to two ethics committees over two years, a 
little over a fifth clearly stated there would be no compensation for trial-related injury, while a little less than half made no mention of it, and some provided caveats, restrictions 
or ambiguous statements.64  
o Compensation for management of study-related injuries/serious adverse events: The same study also examined the management of trial-related injuries and found that only a 
third provided clear statements that free treatment will be provided for trial-related injury, less than a third had no statement on the issue and the rest mentioned restrictions on 
availing free treatment. Authors also found that the two issues, compensation for trial-related injury and for its management/treatment were sometimes mixed together, making 
it unclear which aspect was referred to.64 The ambiguity in the language used to describe compensation for management of study-related injuries in informed consent documents 
and the variations in the type of compensation offered was also mentioned in another study.125 Authors also found that compensation for study-related injuries was mainly 
through ‘reimbursement’ after proving ‘causality’ (which was in contrast to national guidelines). They also noted that most insurance documents examined had incomplete details 
and did not always have their terms and conditions explained.125  
• Informed consent documents (ICDs) – readability and compliance with legal framework and GCP guidelines (n=4):  
o Readability: Two studies evaluated the readability of ICDs used in a clinical research site86 or those submitted alongside research protocols to ethics committees107 by employing 
Western readability tests (Flesch Reading Ease Score and Flesch-Kincaid Grade Level Index). One study employed these tests on Hindi ICDs and reported that the reading level was 
difficult and that it required graduate level education.86 The other mentioned English, Hindi and Punjabi ICDs in the article, but it was unclear which ones the tests were applied 
to, and reported that the readability was close to recommended levels and that there were no changes in readability over three years.107   
BMJ Publishing Group Limited (BMJ) disclaims all liability and responsibility arising from any reliance
Supplemental material placed on this supplemental material which has been supplied by the author(s) BMJ Global Health
 doi: 10.1136/bmjgh-2020-004729:e004729. 6 2021;BMJ Global Health, et al. Paramasivan S
18 
 
o Compliance with legal framework: ICDs from one clinical research site were checked for the presence of the mandatory 19 legally required elements (as per Schedule Y).  More 
than two-thirds of the documents were found to deviate from what the law required. The most common areas that were missing were in relation to appropriate alternative 
treatments and the voluntary nature of participation. All ICDs mentioned that the study was research, the treatment schedule and random assignment of treatment, risks, 
measures to protect confidentiality and the tests/procedures that the patient must have within the trial.95  
o Compliance with GCP guidelines: ICDs submitted to one ethics committee over three years (divided into two time periods) were evaluated for compliance with Indian GCP 
guidelines. Compliance increased over time in relation areas such as basic information (aims, methods), benefits/risks and participant rights. In particular, there was an increase in 
the mention of contact details of research teams, confidentiality of records, right to withdraw, translation to vernacular languages, and compensation for research-related 
injuries. There was a decrease in mention of free treatment and alternative treatments over the two time periods.107 
• Reporting practices (n=6): Studies found that a large number of Indian journal articles did not provide information on ethical approval and/or written informed consent from 
participants and/or guardians in relation to paediatric, psychiatric and HIV/AIDS research.63,71,74,94 Other areas that were found to be sub-optimally reported were the obtaining of assent 
(in paediatric research for children over 7 years old),63 content and language of consent form and process,71 financial compensation, non-financial benefits,94 funding source, conflict of 
interest93,124 and dual ethical approval (in the case of research sponsored by a high-income country and conducted in India).74 One study found that although reporting was sub-optimal, 
it increased over a period of 7 years (2000 to 2007).71 Another study that evaluated editorial policies of Indian journals for endorsement of CONSORT statement and ICJME 
requirements, and the reporting quality of randomised controlled trials in Indian journals in relation to CONSORT statement found these to be less than ideal (although the reporting of 
ethical issues had improved over the years).  Authors also found that methodological and ethical issues were better reported in the clinical trials registry in India than in the journals.124 
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